

Fig. 4. xRibosomal stalling. The protein synthesis defect has been proposed to be due to stalling of translation by pseudoribosomes that have incorporated RNA 19, an incompletely processed transcript reported to accumulate in A3243 mutant cells, in place of 16 S rRNA, or possibly to defective posttranscriptional modification of the tRNA^{Leu(UUR)} [31].

2.6. Aminoacylation

The decrease in level of total tRNA^{Leu(UUR)} observed in the mutant cell lines (46–62% of the control values) could arise either from decreased rate of formation from the corresponding primary heavy strand transcript or from a decreased metabolic stability [32]. The increased amount of RNA 19, which may be a precursor of tRNA^{Leu(UUR)}, was demonstrated in ρ^0 cybrid system as well as somatic tissues in MELAS patients. RNA 19 may suggest the former possibility. On the other hand, the A3243G mutation could perfectly destabilize the tertiary structure of the molecule, and mutant tRNA^{Leu(UUR)} becomes more susceptible to nucleolytic attack [13,33]. It is proposed that mutant tRNA induces the misincorporation of amino acids in mitochondrial DNA encoded polypeptides. However, the demonstration of aminoacylation by mutant tRNA has been little pursued because a chemical amount of the mutant tRNA has not been purified, probably due to technical difficulties. In 2000, Yasukawa succeeded in purifying the mutant tRNA^{Leu(UUR)} molecules in a chemical amount by taking advantage of the solid phase probing method [34], and clearly demonstrated that the mutant tRNA^{Leu(UUR)} is aminoacylated with leucine only. However the extent of aminoacylation of the mutant tRNAs was relatively low. The total amounts of leucyl-tRNA^{Leu(UUR)} with the mutations were estimated to be less than 30% that of the wild-type counterpart [35]. To determine if the decreased fraction of aminoacylated tRNA^{Leu(UUR)} in mutant cells was due to a defect in the ability of mutant tRNA to be aminoacylated by the human mitochondrial leucyl-tRNA synthetase, Park et al. examined the aminoacylation kinetics of wild-type and mutant tRNA^{Leu(UUR)}, using both native and in vitro transcribed tRNA^{Leu(UUR)} [36]. An A3243G mutant tRNA^{Leu(UUR)} was 25-fold less efficiently aminoacylated in vitro, compared to the wild-type tRNA^{Leu(UUR)}. There are many evidences that aminoacylation capacities in tRNA^{Leu(UUR)} gene mutations are reduced [37]. The reduced amount of aminoacyl-tRNA^{Leu(UUR)} with the A3243G mutation could explain the reduction in protein synthesis.

2.7. Modified defects at wobble position in mitochondrial tRNA gene

A number of reports suggest that a decrease of protein synthesis cannot explain the decline in respiratory enzyme activity or in oxygen consumption [38,39]. Even when the mitochondrial protein synthesis rate was normal, the enzymatic activity of complex I was observed to be significantly affected in cybrid clones containing 60% to 95% mutant mtDNA. The muscle form of Complex I deficiency turned out to be MELAS clinically and was confirmed to have an A3243G mutation in all patients [40]. Thus, the decrease in protein synthesis may not itself contribute directly to the pathogenesis caused by mitochondrial

dysfunction. Some unusual mobilities of proteins in SDS-polyacrylamide gel electrophoresis have been reported [18,38], which strongly suggest that amino acids were misincorporated into the proteins synthesized in the mitochondria with the mutant mtDNA. The steady-state amounts of tRNA^{Leu(UUR)} with the A3243G or the T3271C mutation in the respective cybrid clones were about 30% that of the wild-type in the control cybrid clones with wild type mtDNA [35]. In contrast, the steady-state amounts of tRNA^{Phe} and tRNA^{Ile} (encoded up-stream and downstream of the tRNA^{Leu(UUR)} gene) remained unchanged in both the mutant and control cybrid cells. The life span of the mutant tRNA^{Leu(UUR)} is significantly shortened. The half-life of the wild-type tRNA^{Leu(UUR)} was estimated to be about 56 h, whereas those of the A3243G and T3271C mutants were only about 6 and 12 h. Therefore the reduced steady-state levels were due to the shortened life spans of the mutant tRNAs. Yasukawa found that the wild-type tRNA^{Leu(UUR)} contains an unknown modified uridine at the wobble position and that this modification occurs at the uracil base (Fig. 1B). In contrast, this uridine modification is absent in the tRNA^{Leu(UUR)} with a mutation at either np A3243G or T3271C. It is interesting to note that both of the mutant tRNA^{Leu(UUR)} are deficient in the modification at the wobble position despite having mutations at different positions. Modified defects at wobble position in mitochondrial tRNA gene are also demonstrated by primer extension methods [41]. The deficiency in uridine modification at the wobble position in the mutant tRNA^{Leu(UUR)} strongly suggests mistranslation by these mutant tRNAs according to the mitochondrial wobble rule, which is also demonstrated in other tRNA mutation in MERRF (myoclonus epilepsy with ragged-red fibers) [42–45]. Although mutant tRNA^{Leu(UUR)} does not follow the wobble rule, the mutant tRNA^{Leu(UUR)} is aminoacylated with only leucine, not with other aminoacids. The stability and aminoacylation of the mutant tRNA^{Leu(UUR)} were found to be decreased, suggesting that the molecular pathogenesis of MELAS could be a combination of a lowered availability of aminoacyl tRNA^{Leu(UUR)} and defective translation. This is the first observation of a common modification defect affected by different point mutations within a single tRNA gene.

2.8. Threshold effects in various steps in the cell or in the organs

The phenotypic threshold effect observed at the single-cell level could arise when the products of the wild-type mtDNA can no longer “complement” the effects of the mutated ones [46,47]. For instance, a heteroplasmic mutation in mtDNA will result in the co-existence of mutated mRNAs, mutated tRNAs and defective respiratory chain subunits along with their wild-type homologues. These wild-type molecules may be sufficient to support normal function of the organelle until their levels fall below a critical value (threshold), at which point they can no longer compensate for the effect of the mutation, leading to impairment of mitochondrial function. The phenotypic threshold effect is based on this reserve of different macromolecules (mRNAs, tRNAs, subunits), and can then be considered as a protective mechanism providing a safety margin against the effects of deleterious mutations. Above complementation can occur at different levels of mitochondrial gene expression, such as 1) gene transcription, 2) structural stability of the tRNAs, 3) maturation process of the tRNAs, ribosomal RNA, and mRNAs, 4) wobble modification of tRNAs, 5) aminoacylation, 6) translation, 7) molecular assembly of the active form of enzyme complexes in harmony with mitochondrial and nuclear-encoded polypeptides, 8) locate to the mitochondrial inner membrane, 9) biochemical overall function of mitochondria in the cell, 10) biochemical overall function of mitochondria in the organ, 11) original threshold of organ to the mitochondrial energy requirement. The cells which require high energy states, such as neurons, muscles, heart, and kidneys, may be more severely affected by the threshold level of mutation than cell that require low energy levels. The phenotypes in the severity of the disease may influence various factors listed above and are more complicated to elucidate.

2.8.1. Summary of molecular mechanisms of mitochondrial cytopathy

The mutation creates the protein synthesis defects caused by 1) decreased life span of steady state amount of tRNA^{Leu(UUR)} molecules; 2) decreased ratio of aminoacyl-tRNA^{Leu(UUR)} versus uncharged tRNA^{Leu(UUR)} molecules; 3) accumulation of processing intermediates such as RNA 19, 4) wobble modification defects leading to translation defect. The A3243G mutation shows dominant negative effects in the processing system of mitochondrial transcription seen in both trans-mitochondrial cell and muscles in MELAS patients. Molecular mechanisms described above may contribute to respiratory chain enzyme defects, especially complex I, and lead to the mitochondrial cytopathy seen in the MELAS patients. Moreover the A3243G mutation affects the nuclear background [46,47], resulting in a high glycolytic rate, increased lactate production, reduced glucose oxidation, impaired NADH-response, reduced mitochondrial membrane potential, markedly reduced ATP production, deranged cell calcium handling with an increased cytosolic calcium handling with an increased cytosolic calcium load, an increased amount of reactive oxygen species in cybrid cells, reduced insulin secretion, premature aging, and deregulation of genes involved in the metabolism of amino groups and urea genesis. The above mechanism may lead to the cytotoxic edema seen in stroke-like episodes in MELAS.

3. Pathophysiology of mitochondrial angiopathy in MELAS

3.1. Hypotheses of stroke-like episodes in MELAS

The primary cause for stroke-like episodes in young MELAS patients—whether 1) mitochondrial cytopathy, 2) mitochondrial angiopathy, 3) non-ischemic neurovascular cellular mechanism, or combined—remains controversial. Mitochondrial cytopathy is caused by an oxidative phosphorylation defect in neurons, glia, or both as supported by evidence of an oxidative phosphorylation defect described by molecular pathogenesis section. Mitochondrial angiopathy is caused by the endothelial dysfunction evidenced by pathological, vascular physiological [11], or therapeutic findings [9,10]. Finally, the non-ischemic neurovascular cellular mechanism has been recently proposed by the clinical and neuroimaging data by Iizuka et al. [3].

3.2. Mitochondrial angiopathy in MELAS

Mitochondrial angiopathy with degenerative changes in small arteries and arterioles in the brain has been reported in autopsy cases of MELAS patients [6,7]. The mitochondria in the endothelium and smooth muscle cells of cerebral arterioles and capillaries also proliferate in a similar fashion as an area of ragged-red fibers (RRFs). Abnormal accumulation of mitochondria in vascular endothelial cells and smooth muscle cells is responsible for the infarct-like lesions [48]. These blood vessels have been designated as strongly succinate dehydrogenase-reactive vessels (SSVs), since they are rich in abnormal mitochondria [8]. Unlike RRFs and SSVs seen in MERRF and Kearns–Sayre syndrome (KSS), RRFs and SSVs seen in MELAS are typically cytochrome c oxidase (COX) positive, while those seen in MERRF or KSS are mostly COX negative, what is known as the “MELAS paradox” [49]. Since nitric oxide (NO) can bind to the active site of COX and displace heme-bound oxygen, hyperactive COX may decrease the regional NO concentration and lead to the segmental vasodilatation defect in SSV regions. Although infarct-like lesions histopathologically and stroke-like episodes clinically may not be caused simply by occlusion or obliteration of small vessels, this mitochondrial angiopathy, which can be severe in pial arterioles and small arteries, seems to explain the distribution of multiple areas of necrosis [50]. Since MELAS was associated with respiratory dysfunction, accumulated superoxide radical anion may react with nitric oxide to create the powerful oxidant hydroxypennitrite which may induce the neuronal apoptosis or cell damage [51]. All findings, described here,

suggest that mitochondrial angiopathy is a unique and common change in all MELAS brains examined. This pathological abnormality, called mitochondrial angiopathy, may lead to the vasogenic edema seen in stroke-like episodes in MELAS.

3.3. Non-ischemic neurovascular cellular mechanism

Iizuka et al. proposed that the stroke-like episodes in MELAS may reflect neuronal hyperexcitability (epileptic activity), which increases energy demand and creates an imbalance between energy requirements and the adequate availability of ATP due to an oxidative phosphorylation defect, particularly in the susceptible neuronal population [3,52]. The generalized cytopathic mechanism and non-ischemic neurovascular cellular mechanism reflect the so-called mitochondrial cytopathy theory.

3.4. Neuro-imaging analysis in stroke-like episodes

Unlike thrombotic or embolic stroke usually seen in adult patients, the stroke-like episodes in MELAS are atypical because they affect young people and are often triggered by febrile illnesses, migraine-like headaches, seizure, psychological stress, and dehydration. Many neuro-imaging studies have been reported at different phases of onset from stroke-like episodes in MELAS through the use of computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), single emission computed tomography (SPECT), and positron emission tomography (PET). Calcification of the basal ganglia is frequently observed in MELAS by CT even before starting the stroke-like episodes. MRI scans of acute stroke-like events show an increased signal on T2-weighted or on fluid attenuation inversion recovery (FLAIR). The regions do not conform to the territories of large cerebral arteries but rather affect the cortex and subjacent white matter with sparing of deeper white matter. Acute changes in these regions may fluctuate, migrate, or even disappear during the time course. Cerebral angiograms in MELAS patients have confirmed absence of large-vessel pathology by demonstrating normal results, increased size of caliber arteries, veins, or capillary blush with early venous filling, with the exception of several case reports [53,54]. MRS studied revealed that the decrease in N-acetylaspartate (NAA), which is thought to be an amino acid specific to neurons, and an increase of lactate, which is reflected of anaerobic metabolism by ¹H-magnetic resonance spectroscopy (¹H-MRS), were in evidence in the affected areas at acute stroke-like episodes. Kubota et al. reported that L-arginine infusion protect the accumulation of lactate by MRS analysis in stroke-like episodes in MELAS [55]. The increased level of lactate on ¹H-MRS is also recognized even in normal appearing regions [56]. Phosphorus MRS studies have shown decreased levels of high-energy phosphate compounds in the brains of MELAS patients [57], showing that mitochondrial cytopathy constantly exists in the MELAS patient. SPECT studies have generally revealed that the increased tracer accumulation was reported in acute (several days) and subacute stage (month) from the onset of stroke-like episodes and lasted for several months. In the chronic stage (several months or years later), the decreased tracer accumulation was reported. However, in the hyperacute stage (3 h after the onset of stroke-like episodes), we observed hypoperfusion by SPM-SPECT analysis [58]. Moreover, the hypoperfusion and the hyperperfusion areas are both demonstrated in the MELAS patients not only at an acute phase but at an interictal phase, showing that MELAS has inappropriate cerebral circulation [54]. Moreover, MELAS showed hypoperfusion in the posterior cingulate cortex by SPM-SPECT, which is the common finding in Alzheimer disease, and may be related to the dementia state usually seen in the progressive stage of MELAS. There are several PET studies using (rCMRO₂), [⁶²Cu]-diacetyl bis (N4-methylthiosemicarbazone) (⁶²Cu-ATSM), and [¹⁸F]-fluorodeoxyglucose (¹⁸FDG) in stroke-like regions [59,60]. All of the PET studies of

patients have revealed decreased oxygen consumption relative to glucose utilization, further confirming the impairment of oxidative phosphorylation [61]. The dissociation in PET findings between cerebral glucose and oxygen metabolism may be the characteristic feature of MELAS, suggesting the mitochondrial cytopathy theory or non-ischemic neurovascular cellular mechanism. Diffusion-weighted (DWI) imaging is a new MRI technique for detecting diffusion of water molecules. Using DWI, local water mobility can be assayed as the absolute value of tissue water and expressed as the apparent diffusion coefficient (ADC). It has been shown using a stroke model in rats that ADC (a marker for cytotoxic brain edema) significantly declined within the first 5–10 min after stroke onset, while T2-relaxation time (a marker for vasogenic brain edema) increased as early as at the first T2-imaging time-point (20–35 min after embolization) [62]. The acute phase of stroke-like lesions in MELAS appear as a high signal on DWI with normal or increased ADC values, suggesting vasogenic edema which support the mitochondrial angiopathy theory [63,64]. On the contrary, many case reports found a decrease in ADC, which suggests mitochondrial cytopathy theory [65]. Recently, it was reported that increased and decreased ADC portions are mixed in stroke-like lesions, in which the increased ADC portion showed disappearance of the lesions thereafter, and the decreased portion showed persistent lesions. They suggested that there might be different levels of mitochondrial energetic transport impairment, correlated with cellular dysfunction. Specifically, this would be a mild energy failure resulting in moderate cellular dysfunction, responsible for vasogenic edema (high ADCs) and a severe energy failure resulting in irreversible cellular failure with cytotoxic edema (low ADCs) [66].

3.5. Endothelial dysfunction in MELAS

Physiologically, MELAS patients have a decreased vasodilation capacity in small arteries examined by flow mediated vasodilatation

(FMD) methods, sized from 3 to 5 mm in their diameter [11]. MELAS patients have significantly decreased levels of L-arginine at acute phase of stroke-like episodes, which plays an important role in endothelial-dependent vascular relaxation [67], vasodilatation may be more severely affected in MELAS. Since MELAS patients have defective respiratory chain enzyme activities, a high NADH/NAD⁺ ratio inhibits the NO synthetase reaction to cause a decreased production of NO at the endothelial cells or smooth muscle cells in the artery. In addition, ADMA (asymmetrical dimethyl-arginine), a risk factor of ischemic heart disorders, was relatively increased in MELAS patients [10], which may lead to a negative effect on the endothelial NO synthetase activity. If hyperactive COX may decrease the regional NO concentration as described in “MELAS paradox” [49], all of the above scenarios lead to the segmental vasodilatation defect especially in the segment of SSV re-gions in the cerebral artery or arterioles. The investigator-mediated clinical trial of L-arginine on MELAS (Dr. Koga as a principle investigator) to cure the symptoms of stroke-like episodes at acute phase, and to prevent or decrease the severity of stroke-like episodes at interictal phase of MELAS are on-going at 15 institutions of university hospital in Japan.

3.5.1. Summary of mitochondrial angiopathy and L-arginine effects

Pathophysiological mechanisms of mitochondrial angiopathy and the effects of L-arginine are summarized in Fig. 5.

4. Conclusion and future direction

The possible pathogenic mechanism of stroke-like episodes in MELAS may not be simple but complicated as described by the mechanisms in mitochondrial cytopathy and in mitochondrial angiopathy. Mitochondrial cytopathy has been demonstrated clearly as molecular and cellular defects by trans-mitochondrial cellular models. Mitochondrial angiopathy also has been demonstrated in brain and muscle pathology and vascular physiology. Although the results of




Fig. 5. Pathogenic mechanisms of mitochondrial angiopathy in MELAS. Segmental occlusions of small artery or arterioles are evident in brain as well as in muscle pathology, in which abnormal accumulations of mitochondria have seen in endothelial and smooth muscle layers [6,7]. This phenomenon is recognized as SSVs in muscle and brain in MELAS [8], whereby mitochondrial function is more profoundly defective than the rest of the vessels, and demonstrated as endothelial dysfunction by FMD physiologically [11]. In MELAS patients, decreased levels of L-arginine is reported at acute phase of stroke-like episodes, a potent donor of NO, is also responsible for NO-dependent vascular dilatation defect. The decreased NAD/NADH ratio and accumulation of superoxide come from respiratory chain deficiency results in the inhibition of NO synthetase at generation process and decrease NO molecules by binding to create hydroxypemnitrite, also contribute to the NO-dependent vasodilation abnormality. Since SSVs has usually high COX-positive feature histochemically, high COX activity decrease the residual NO molecules by binding to COX reactive center. The mental stress, dehydration, fever and cold exposure are also very important factors to increase the risk of the stroke-like episodes in MELAS.

neuro-imaging studies are controversial and are difficult to evaluate, there are several specific findings which may lead to the pathophysiology of stroke-like episodes in MELAS. We have to elucidate what is the trigger of stroke-like episodes in MELAS in future. Currently L-arginine therapy, to cure the symptoms of stroke-like episodes at acute phase, and to prevent or decrease the severity of stroke-like episodes at interictal phase of MELAS, is the most promising therapy for this incurable disorder. Global clinical trial of L-arginine on MELAS using randomized double blind placebo control protocol may be done in the nearer future.

References

- [1] S.G. Pavliakis, P.C. Phillips, S. DiMauro, D.C. De Vivo, L.P. Rowland, *Ann. Neurol.* 16 (1984) 481–488.
- [2] S. DiMauro and M. Hirano. MELAS, R.A. Pagon, T.C. Bird, C.R. Dolan, K. Stephens and editors, Seattle (WA), University of Washington Seattle, *Gene reviews* [Internet; <http://www.ncbi.nlm.nih.gov/books/NBK1233/>] (1993) updated 2010 Oct 14
- [3] T. Iizuka, F. Sakai, *Future Neurol.* 5 (2010) 61–83.
- [4] Y. Goto, I. Nonaka, A. Horai, *Nature* 348 (1990) 651–653.
- [5] Y. Goto, S. Horai, T. Matsuoka, Y. Koga, K. Nihei, M. Kobayashi, I. Nonaka, *Neurology* 42 (1992) 545–550.
- [6] E. Ohama, S. Ohara, F. Ikuta, K. Tanaka, M. Nishizawa, T. Miyatake, *Acta Neuropathol.* 74 (1987) 226–233.
- [7] M. Kishi, Y. Yamamura, T. Kurihara, N. Fukuhara, K. Tsuruta, S. Matsukura, T. Hayashi, M. Nakagawa, M. Kuriyama, *J. Neurol. Sci.* 86 (1988) 31–40.
- [8] H. Hasegawa, T. Matsuoka, Y. Goto, I. Nonaka, *Ann. Neurol.* 29 (1991) 601–605.
- [9] Y. Koga, M. Ishibashi, I. Ueki, S. Yatsuga, R. Fukiyama, Y. Akita, T. Matsuishi, *Neurology* 58 (2002) 827–828.
- [10] Y. Koga, Y. Akita, J. Nishioka, S. Yatsuga, N. Povalko, Y. Tanabe, S. Fujimoto, T. Matsuishi, *Neurology* 64 (2005) 710–712.
- [11] Y. Koga, Y. Akita, N. Junko, S. Yatsuga, N. Povalko, R. Fukiyama, M. Ishii, T. Matsuishi, *Neurology* 66 (2006) 1766–1769.
- [12] J.P. Goddard, *Prog. Biophys. Mol. Biol.* 32 (1977) 233–308.
- [13] M.D. Roy, L.M. Wittenhagen, S.O. Kelley, *RNA* 11 (2005) 254–260.
- [14] J. Finsterer, *Acta Neurol. Scand.* 116 (2007) 1–14.
- [15] B. Sohm, M. Frugier, H. Brule, K. Olszak, A. Przykorska, C. Florentz, *J. Mol. Biol.* 328 (2003) 995–1010.
- [16] M.P. King, G. Attardi, *Cell* 52 (1998) 811–819.
- [17] M.P. King, G. Attardi, *Science* 246 (1989) 500–503.
- [18] A. Chomyn, A. Martinuzzi, M. Yoneda, A. Daga, O. Hurko, D. Johns, S.T. Lai, I. Nonaka, S. Angelini, G. Attardi, *Proc. Natl. Acad. Sci. U. S. A.* 89 (1992) 4221–4225.
- [19] M.P. King, Y. Koga, M. Davidson, E.A. Schon, *Mol. Cell. Biol.* 12 (1992) 480–490.
- [20] R. Gelfand, G. Attardi, *Mol. Cell. Biol.* 1 (1981) 497–511.
- [21] J. Montoya, G.L. Gaines, G. Attardi, *Cell* 34 (1983) 151–159.
- [22] B. Kruse, N. Narasimhan, G. Attardi, *Cell* 58 (1989) 391–397.
- [23] J.F. Hess, M.A. Parisi, J.L. Bennett, D.A. Clayton, *Nature* 351 (1991) 236–239.
- [24] Y. Koga, M. Davidson, E.A. Schon, M.P. King, *Nucleic Acids Res.* 21 (1993) 657–662.
- [25] L. Levinger, I. Oestreich, C. Florentz, M. Morl, *J. Mol. Biol.* 337 (2004) 535–544.
- [26] P. Kaufmann, Y. Koga, S. Shanske, M. Hirano, S. DiMauro, M.P. King, E.A. Schon, *Ann. Neurol.* 40 (1996) 172–180.
- [27] L.A. Bindoff, N. Howell, J. Poulton, D.A. McCullough, K.J. Morten, R.N. Lightowlers, D.M. Turnbull, K. Weber, *J. Biol. Chem.* 268 (1993) 19559–19564.
- [28] Y. Koga, M. Yoshino, H. Kato, *Ann. Neurol.* 43 (1998) 835.
- [29] Y. Koga, M. Davidson, E.A. Schon EA, M.P. King, *Muscle Nerve* 3 (1995) S119–S123 suppl.
- [30] A. Koga, Y. Koga, Y. Akita, M. Yoshino, H. Kato, *Neuromuscul. Disord.* 13 (2003) 259–262.
- [31] E.A. Schon, Y. Koga, M. Davidson, C.T. Moraes, M.P. King, *Biochem. Biophys. Acta* 1101 (1992) 206–209.
- [32] A. Chomyn, J.A. Enriquez, V. Micol, P. Fernandez-Silva, G. Attardi, *J. Biol. Chem.* 275 (2000) 19198–19209.
- [33] M. Helm, C. Florentz, A. Chomyn, G. Attardi, *Nucleic Acids Res.* 27 (1999) 756–763.
- [34] K. Wakita, Y. Watanabe, T. Yokogawa, Y. Kumazawa, S. Nakamura, T. Ueda, K. Watanabe, K. Nishikawa, *Nucleic Acids Res.* 22 (1994) 347–353.
- [35] T. Yasukawa, T. Suzuki, T. Suzuki, T. Ueda, S. Ohta, K. Watanabe, *J. Biol. Chem.* 275 (2000) 4251–4257.
- [36] H. Park, M. Davidson, M.P. King, *Biochemistry* 42 (2003) 958–964.
- [37] R. Hao, Y.N. Yao, Y.G. Zheng, M.G. Xu, E.D. Wang, *FEBS Lett.* 578 (2004) 135–139.
- [38] D.R. Dunbar, P.A. Moonie, M. Zeviani, J. Holt, *Hum. Mol. Genet.* 5 (1996) 123–129.
- [39] H. Flierl, P. Reichmann, J. Seibel, *Biol. Chem.* 272 (1997) 27189–27196.
- [40] Y. Koga, I. Nonaka, M. Kobayashi, M. Tojyo, K. Nihei, *Ann. Neurol.* 24 (1988) 749–756.
- [41] Y. Kirino, T. Yasukawa, S. Ohta, S. Akira, K. Ishihara, K. Watanabe, T. Suzuki, *Proc. Natl. Acad. Sci. U. S. A.* 101 (2004) 15070–15075.
- [42] T. Yasukawa, T. Suzuki, N. Ishii, S. Ohta, K. Watanabe, *EMBO J.* 20 (2001) 4794–4802.
- [43] T. Yasukawa, T. Suzuki, N. Ishii, T. Ueda, S. Ohta, K. Watanabe, *FEBS Lett.* 467 (2000) 175–178.
- [44] Y. Kirino, T. Yasukawa, S.K. Marjavaara, H.T. Jacobs, I.J. Holt, K. Watanabe, T. Suzuki, *Hum. Mol. Genet.* 15 (2006) 897–904.
- [45] T. Suzuki, T. Suzuki, T. Wada, K. Saigo, K. Watanabe, *EMBO J.* 21 (2002) 6581–6589.
- [46] R. Rossignol, M. Malgat, J.P. Mazat, T. Letellier, *J. Biol. Chem.* 274 (1999) 33426–33432.
- [47] R. Rossignol, B. Faustin, C. Rocher, M. Malgat, J.P. Mazat, T. Letellier, *Biochem. J.* 370 (2003) 751–762.
- [48] R. Sakuta, I. Nonaka, *Ann. Neurol.* 25 (1989) 594–601.
- [49] A. Naini, P. Kaufmann, S. Shanske, K. Engelstad, D.C. De Vivo, E.A. Schon, *J. Neurol. Sci.* 229–230 (2005) 187–193.
- [50] C. Tanahashi, A. Nakayama, M. Yoshida, M. Ito, N. Mori, Y. Hashizume, *Acta Neuropathol.* 99 (2000) 31–38.
- [51] M.A. Moro, A. Almeida, J.P. Bolanos, I. Lizasoain, *Free Radical Biology & Medicine* 39 (2005) 1291–1304.
- [52] T. Iizuka, F. Sakai, T. Ide, S. Miyakawa, M. Sato, S. Yoshii, *J. Neurol. Sci.* 257 (2007) 126–138.
- [53] A. Noguchi, Y. Shoji, M. Matsumori, K. Komatsu, G. Takada, *Pediatr. Neurol.* 33 (2005) 70–71.
- [54] T. Iizuka, Y. Goto, S. Miyakawa, M. Sato, Z. Wang, K. Suzuki, J. Hamada, A. Kurata, F. Sakai, *J. Neurol. Sci.* 278 (2009) 35–40.
- [55] M. Kubota, Y. Sakakihara, M. Mori, T. Yamagata, M. Momoi-Yoshida, *Brain Dev.* 26 (2004) 481–483.
- [56] E. Wilichowski, P.J. Pouwels, J. Frahm, F. Hanefeld, *Neuropediatrics* 30 (1999) 256–263.
- [57] P. Kaufmann, D.C. Shungu, M.C. Sano, S. Jhung, K. Engelstad, E. Mitsis, X. Mao, S. Shanske, M. Hirano, S. DiMauro, D.C. De Vivo, *Neurology* 62 (2004) 1297–1302.
- [58] J. Nishioka, Y. Akita, S. Yatsuga, K. Katayama, T. Matsuishi, M. Ishibashi, Y. Koga, *Brain Dev.* 30 (2008) 100–105.
- [59] M. Ikawa, H. Okazawa, K. Arakawa, T. Kudo, H. Kimura, Y. Fujibayashi, M. Kuriyama, M. Yoneda, *Mitochondrion* 9 (2009) 144–148.
- [60] T. Nariiai, K. Ohno, Y. Ohta, K. Hirakawa, K. Ishii, M. Senda, *J. Neuroimaging* 11 (2001) 325–329.
- [61] M.J. Molnár, A. Valikovics, S. Molnár, L. Trón, P. Diószeghy, F. Mechler, B. Gulyás, *Neurology* 55 (2000) 544–548.
- [62] T. Gerriets, E. Stolz, M. Walberer, C. Müller, A. Kluge, M. Kaps, M. Fisher, G. Bachmann, *Brain Res. Protoc.* 12 (2004) 137–143.
- [63] T. Ohshita, M. Oka, Y. Imon, C. Watanabe, S. Katayama, S. Yamaguchi, T. Kajima, Y. Mimori, S. Nakamura, *Neuroradiology* 42 (2000) 651–656.
- [64] H. Ito, K. Mori, M. Harada, M. Minato, E. Naito, M. Takeuchi, Y. Kuroda, S. Kagami, *Brain Dev.* 30 (2008) 483–488.
- [65] X.Y. Wang, K. Noguchi, S. Takashima, N. Hayashi, S. Ogawa, H. Seto, *Neuroradiology* 45 (2003) 640–643.
- [66] S. Stoquart-Elsankari, P. Lehmann, B. Périn, C. Gondry-Jouet, O. Godefroy, *J. Neurol.* 255 (2008) 1593–1595.
- [67] X.L. Wang, A.S. Sim, R.F. Badenhop, R.M. McCredie, D.E. Wilcken, *Nat. Med.* 2 (1996) 41–45.

Original article

Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1 α gene

Yasutoshi Koga^{a,*}, Nataliya Povalko^a, Koujyu Katayama^a, Noriko Kakimoto^a,
Toyojiro Matsuishi^a, Etsuo Naito^b, Masashi Tanaka^c

^a Department of Pediatrics and Child Health, Kurume University Graduate School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830-0011, Japan

^b Department of Pediatrics, School of Medicine, Tokushima University, Tokushima 770-8501, Japan

^c Department of Genomics for Longevity and Health, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan

Received 5 April 2010; received in revised form 16 January 2011; accepted 1 March 2011

Abstract

Leigh syndrome (LS) is a progressive untreatable degenerating mitochondrial disorder caused by either mitochondrial or nuclear DNA mutations. A patient was a second child of unconanguineous parents. On the third day of birth, he was transferred to neonatal intensive care units because of severe lactic acidosis. Since he was showing continuous lactic acidosis, the oral supplementation of dichloroacetate (DCA) was introduced on 31st day of birth at initial dose of 50 mg/kg, followed by maintenance dose of 25 mg/kg/every 12 h. The patient was diagnosed with LS due to a point mutation of an A–C at nucleotide 599 in exon 6 in the pyruvate dehydrogenase E1 α gene, resulting in the substitution of aspartate for threonine at position 200 (N200T). Although the concentrations of lactate and pyruvate in blood were slightly decreased, his clinical conditions were deteriorating progressively. In order to overcome the mitochondrial or cytosolic energy crisis indicated by lactic acidosis as well as clinical symptoms, we terminated the DCA and administered 0.5 g/kg/day TID of sodium pyruvate orally. We analyzed the therapeutic effects of DCA or sodium pyruvate in the patient, and found that pyruvate therapy significantly decreased lactate, pyruvate and alanine levels, showed no adverse effects such as severe neuropathy seen in DCA, and had better clinical response on development and epilepsy. Though the efficacy of pyruvate on LS will be evaluated by randomized double-blind placebo-controlled study design in future, pyruvate therapy is a possible candidate for therapeutic choice for currently incurable mitochondrial disorders such as LS.

© 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Keywords: Leigh syndrome; PDH E1 α mutation; Pyruvate; Lactic acidosis; Therapy

1. Introduction

LS, originally reported as subacute necrotizing encephalomyelopathy by Dr. Denis Leigh in 1951 [1], is an early-onset progressive neurodegenerative disorder characterized by developmental delay or regression, lactic acidosis, and bilateral symmetrical lesion in the basal ganglia, thalamus, and brainstem [2]. The clinical presentations of the disease are heterogeneous, due to the

severity of biochemical defects caused by mutations in both nuclear and mitochondrial genes involved in energy metabolism. Though many molecular defects are reported to be associated with LS [3], the underlying gene defects remain unidentified in nearly half of the patients [4,5]. Since LS is associated mainly with the respiratory chain deficiency, there is no established treatment except for a limited number of patients such as those with thiamine-responsive pyruvate dehydrogenase deficiency [6], or those with defects in the biosynthetic pathway of coenzyme Q [7]. We have proposed that pyruvate has a therapeutic potential for mitochondrial diseases, because: (a) pyruvate can stimulate the

* Corresponding author. Tel.: +81 942 31 7565; fax: +81 942 38 1792.

E-mail address: yasukoga@med.kurume-u.ac.jp (Y. Koga).

glycolytic pathway by reducing the NADH/NAD ratio in the cytoplasm, (b) pyruvate can activate PDHC by inhibiting pyruvate dehydrogenase kinase, and (c) pyruvate can scavenge hydrogen peroxide by non-enzymatic reaction [8]. Recently, we reported that pyruvate produced a slightly favorable change in the plasma lactate and pyruvate levels in LS with cytochrome c oxidase deficiency [9]. In the present report, we describe a clinical experience of pyruvate therapy in a child with LS having PDH deficiency caused by a novel mutation in PDH E1 α gene.

2. Patient and methods

2.1. Patient

The 5-years-old boy, presented as severe psychomotor retardation with severe lactic acidosis, was born

weighing 1797 g at full term gestational age as the second child of unconsanguineous parents. He was transferred to neonatal intensive care units because of fatal distress with the severe lactic acidosis. The concentrations of lactate and pyruvate in blood were 6–10 times higher than normal range, with normal lactate/pyruvate ratio (Table 1). He was under respiratory care with medication of severe metabolic acidosis. Amino-gram of his plasma showed an elevated alanine concentration of 1.82 mM (normal range, 0.21–0.52). Since he was showing continuous lactic acidosis, the oral supplementation of DCA was introduced on 31st day of birth at initial dose of 50 mg/kg, followed by maintenance dose of 25 mg/kg/every 12 h. Though he showed severe floppy infant, his mechanical ventilation has been terminated at the 45th day of birth, and starting oral administration of ingredient nutrient. Although the concentrations of lactate and pyruvate in blood were

Table 1
Biochemical parameters during therapy with none, DCA, or pyruvate.

	None (<i>n</i> = 8)	DCA therapy (<i>n</i> = 12)	Pyruvate therapy (<i>n</i> = 10)
Lactate (mM) (normal: 0.03–0.17) (Range: minimum–maximum)	9.6 ± 0.54 (8.70–10.10)	8.6 ± 2.63 (3.56–12.70)	5.28 ± 1.73 ^{a,b} (2.73–7.75)
Pyruvate (mM) (normal: 0.003–0.10) (Range: minimum–maximum)	0.69 ± 0.13 (0.49–0.82)	0.61 ± 0.19 (0.31–0.93)	0.42 ± 0.13 ^{a,b} (0.26–0.68)
L/P ratio (normal: 10–15) (Range: minimum–maximum)	14.5 ± 3.10 (10.6–18.7)	14.2 ± 2.12 (11.5–17.9)	12.6 ± 1.52 (10.5–15.1)
Alanine (mM) (normal: 0.21–0.52) (Range: minimum–maximum)	1.7 ± 0.28 (1.11–1.82)	1.13 ± 0.27 ^a (0.76–1.51)	0.77 ± 0.38 ^a (0.39–1.42)

All data are presented as mean ± SD during each treatments.

Lactate, pyruvate L/P ratio, and alanine were analyzed the significance between periods of none, DCA and pyruvate therapy using the two-tailed Mann–Whitney *U*-test. *P* value less than 0.05 showed significant.

^a It showed significance between none and DCA or pyruvate therapy.

^b It showed significance between DCA and pyruvate therapy. *n*: number of measurements.

Table 2
Entire clinical course and symptoms.

	Clinical course		
	None	DCA	Pyruvate
Study periods	1 month (1 m)	17 months (2–18 m)	58 months (1 year 6 months–6 years 4 months)
Hospitalization (day)	31	124	3
Emergency visit (time)	0	14	4
Diagnosis by EEG	Infantile epilepsy	West syndrome or Lennox–Gastaut syndrome	Lennox–Gastaut syndrome
<i>Convulsion</i>			
Frequency	15 or more/days	18 or more/days	2–3/months
Duration	5–15 s/Epilepsy	5–20 s/Epilepsy	5–10 s/Epilepsy
Series formation	None	Series formation	No series formation
Anticonvulsants	Phenobarbital 20 mg/kg/day	Carbamazepine 10 mg/kg/day Valproate 10–15 mg/kg/day Clobazam 1.0 mg/kg/day Zonisamide 2–4 mg/kg/day	Carbamazepine 10 mg/kg/day Valproate 15 mg/kg/day Clobazam 1.5 mg/kg/day Zonisamide 2–4 mg/kg/day
JMDRS	58	58	57
Developments	Severe floppy infant Respiratory care	Cannot head control Cannot sit alone Cannot rolling over Floppy infant Eating mainly by S-tube	Floppy infant Head control (21 months) Rolling over (42 months) Sit alone (56 months) Eating mainly by mouth

slightly decreased by DCA, his clinical conditions were deteriorating progressively. He could not fix the head control, and roll over at 6 months of age. He was diagnosed with West syndrome at 6 months-old because of his intractable generalized convulsions. Though he received two types of anti-convulsants as shown in Table 2, his convulsion did not stop and showed several seizures a day with series formation. Brain MRI on 7-months-old showed a premature myelination and atrophy in frontal lobe with callosal hypoplasia, and brainstem abnormality. He showed severe floppiness, loose head control, inability to sit alone and roll over, feeding difficulty, and no significant words at the age of 18 months-old. His EEG pattern changed to Lennox–Gastaut syndrome at that time (Fig. 1A). Nerve conduction velocity in both motor and sensory nerve showed low amplitude with delayed velocity indicating

severe neuropathy. At this point, we thought that severe neuropathy seen in the patient may caused by the severe adverse effects of DCA, since he received the DCA supplementation for more than 17 months period. Because of the severe neuropathy, we decided to terminate the DCA at his age of 18 months-old, and after received written informed consent, we started the oral supplementation of sodium pyruvate at 0.5 g/kg/day TID. Three months later, he started to roll over and showed the facial expression of happiness and sadness. He could start to chatter and swallow the liquid food. Six months after starting pyruvate supplementation, he had almost no epileptic seizure and was demonstrated the significant improvement by EEG (Fig. 1B). The entire clinical course is summarized in Fig. 2 and Table 2.

The lactate and pyruvate concentrations in cerebral spinal fluid were 8.23 mM, and 1.26 mM under the period of DCA therapy, and 4.61 mM and 0.68 mM under the period of pyruvate therapy (Fig. 2).




Fig. 1. (A) EEG taken at 18 months old. A grossly abnormal inter-ictal EEG showed continuous, high-amplitude, sharp-slow-waves or spike-slow-waves indicating a multifocal and generalizing sharp-slow-wave-discharges at 1.5–2.5 Hz. Patient showed intractable epilepsy with 15–20 times a day of grandmal, and/or myoclonic type seizure. (B) EEG taken at 36 months old. An abnormal inter-ictal EEG pattern showed with continuous, sharp-slow-waves or spike-slow-waves. However it showed low-amplitude and less multi-focality. Patient showed no grandmal or myoclonic type seizure by daily base frequency.

2.2. Lactate, pyruvate, L/P ratio and alanine determination

In order to investigate the energy state of patient in each time period of therapy, we measured the plasma level of lactate, pyruvate and aminogram including alanine, 8 times in the periods of 31 days with free of DCA and pyruvate, 12 times in 17 months during DCA therapy, and 10 times in 58 months during pyruvate therapy. Analysis of amino acids was performed on protein-free extracts of fresh plasma using described methods.

2.3. Enzyme assays

The PDHC activity in cultured skin fibroblasts was assayed using two different concentrations of TPP (0.4 and 1104 mM) after the activation of PDHC using DCA as previously described [10].

2.4. Genetic analysis

Mutation analysis of the E1 α gene, a major cause of PDHC deficiency, was performed using genomic DNA from cultured skin fibroblasts. For the genetic analysis of the 11 exons of the E1 α gene, the individual exons were amplified using primer pairs and conditions as described previously [11].

2.5. Statistical analysis

Statistical analysis of the biochemical data including lactate, pyruvate, L/P ratio, and alanine was performed using two-tailed Mann–Whitney *U*-test or Student's *t*-test. A value of $P < 0.05$ was considered as statistically significant.




Fig. 2. Entire clinical course.

3. Results

Since patient showed lactic acidosis with normal lactate/pyruvate ratio, we measure the PDHC activity in cultured skin fibroblasts cells. The PDHC activity was 0.94 in the presence of DCA and 0.4 mM TPP (normal: 4.07 ± 0.68 nmol/min/mg protein). Mutation analysis of PDH E1 α subunits revealed a point mutation of an A–C at nucleotide 599 in exon 6, resulting in the substitution of aspartate for threonine at position 200 (N200T). Though this mutation has not been reported before, we considered it as the responsible gene defect in this patient because; (1) no other mutations were found in entire PDH E1 α gene, (2) conserved amino acid in different species, (3) mother has the mutation in hemizygous condition, and (4) no same mutation found in 50 normal females.

The laboratory data before, and after the treatment by DCA, and after pyruvate treatment are shown in Table 1 and Fig. 2. The concentration of lactate and pyruvate in blood before the treatment was 51–58 times higher than normal range, with normal lactate/pyruvate ratio (Table 1). The concentration of alanine was also increased 2.1–3.5 times higher than normal range. After the treatment by DCA, though the concentration of lactate and pyruvate showed no significance, the concentration of alanine was significantly decreased. The patient showed intractable seizures, and decreased the activity of daily living. After the treatment by pyruvate, the concentration of lactate and pyruvate were significantly decreased in comparison with those without therapy, and with DCA treatment, with significantly decreased level of alanine (Table 1 and Fig. 2). The concentrations

of lactate and pyruvate in the CSF were also significantly decreased with significantly decreased plasma level of alanine (Fig. 2).

4. Discussion

LS, the most dominant sub-type of mitochondrial disorders in children, are clinically more severe and patients usually die before the first decade of the life. In another words, LS showed the most severe cytopathy among subtypes of mitochondrial disorders. Therapeutic target of mitochondrial angiopathy is now on-going of L-arginine as an investigator-mediated clinical trial on MELAS [12]. However there are no clinical trial of therapeutic approach for mitochondrial cytopathy especially LS. Since the severe adverse events of DCA reported in 2006 [13], the new therapeutic drugs to prevent or improve the mitochondrial cytopathy or lactic acidosis have to be developed as a substitute for DCA.

In the present study, we reported a patient with LS caused by a novel PDH E1 α mutation who responded to pyruvate administration for 3 years period. Pyruvate therapy significantly decreased the lactate, pyruvate and alanine levels, showed no adverse effects such as severe neuropathy seen in this patient under the DCA therapy, and had better clinical response on development and epilepsy. It was reported that pyruvate percolates through the blood brain barrier via monocarboxylate transporters and provides an excellent energy state for neurons and astroglia [14]. As shown in our patient (Fig. 2), pyruvates decreased lactate and alanine levels not only in blood but in CSF, and improved the electroencephalogram in our patient, suggested that pyruvate

may pass through blood-brain barrier and improve the metabolic condition in the brain in our patient. We have proposed that pyruvate has a therapeutic potential for mitochondrial diseases, because: (a) pyruvate can stimulate the glycolytic pathway by reducing the NADH/NAD ratio in the cytoplasm [8], (b) pyruvate can activate the pyruvate dehydrogenase complex (PDHC) by inhibiting the pyruvate dehydrogenase kinase [8,9], and (c) pyruvate can scavenge the hydrogen peroxide by a non-enzymatic reaction [15]. Pyruvate improved the hemodynamic condition by intracoronary infusion in patients with congestive heart failure [16,17], or the neurological recovery following cardiopulmonary arrest and resuscitation [18]. In our patient, we determined the daily supplement of pyruvate by the presence of diarrhea as adverse effects or by the capacity of amount of oral administration. In our patient, daily administration of sodium pyruvate resulted in 0.5d/kg/day TID. The exact pharmacological mechanisms why serum pyruvate is also decreased after the pyruvate therapy, have to be clarified in future study, by using proteome analysis or comprehensive multiple analysis of total cell metabolism.


Considering the progressive nature of LS, pyruvate may prevent the neurodegeneration and lactic acidosis in our patient. Though the efficacy of pyruvate on LS will be evaluated by randomized double-blind placebo-controlled study design in future, pyruvate therapy is a possible candidate for therapeutic choice for currently incurable mitochondrial disorders such as LS.

Acknowledgements

Authors thank to the Prof. Shinichi Hirose for treating the initial therapy and for providing the initial laboratory data. This work was supported in part by Grants #13670853 (Y.K.), and #16390308 (Y.K.) from the Ministry of Culture and Education in Japan, and #CCT-B-1803 (Y.K.) from Evidence-based Medicine, Ministry of Health, Labor and Welfare in Japan. N.P. is a recipient of grant in aid for young investigator from Heiwa Research Foundation in Japan. This work was supported in part by a grants from the program Grants-in-Aid for Scientific Research [A-22240072, B-21390459, and C-21590411 to M.T.]; by Grant 20B-13 from the program Research Grants for Nervous and Mental Disorders of the Ministry of Health, Labour, and Welfare (to Y. K. and M.T.); and by grants for scientific research from the Takeda Science Foundation (to M.T.)

References

- [1] Leigh D. Subacute necrotizing encephalomyelopathy in an infant. *J Neurol Neurosurg Psychiatry* 1951;14:216–21.
- [2] Finsterer J. Leigh and Leigh-like syndrome in children and adults. *Pediatr Neurol* 2008;39:223–35.
- [3] Robinson BH. Lactic acidemia and mitochondrial disease. *Mol Genet Metab* 2006;89:3–13.
- [4] Rahman S, Blok RB, Dahl HH, Danks DN, Kirby DM, Chow CW, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. *Ann Neurol* 1996;39:343–51.
- [5] Morris AA, Leonard JV, Brown GK, Bidouki SK, Bindoff LA, Woodward CE, et al. Deficiency of respiratory chain complex I is a common cause of Leigh disease. *Ann Neurol* 1996;40:25–30.
- [6] Naito E, Ito M, Yokota I, Saijo T, Ogawa Y, Kuroda Y. Diagnosis and molecular analysis of three male patients with thiamine-responsive pyruvate dehydrogenase complex deficiency. *J Neurol Sci* 2002;201:33–7.
- [7] Quinzii CM, Hirano M, DiMauro S. CoQ10 deficiency diseases in adults. *Mitochondrion* 2007;7:S122–6.
- [8] Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y. Therapeutic potential of pyruvate therapy for mitochondrial diseases. *Mitochondrion* 2007;7:399–401.
- [9] Komaki H, Nishigaki Y, Fuku N, Hosoya H, Murayama K, Ohtake A, et al. Pyruvate therapy on Leigh syndrome due to cytochrome *c* oxidase deficiency. *Biochim Biophys Acta* 2010;1800:313–5.
- [10] Naito E, Ito M, Takeda E, Yokota I, Yoshijima S, Kuroda Y. Molecular analysis of abnormal pyruvate dehydrogenase in a patient with thiamine-responsive congenital lactic acidemia. *Pediatr Res* 1994;36:340–6.
- [11] Matsuda J, Ito M, Naito E, Yokota I, Kuroda Y. DNA diagnosis of pyruvate dehydrogenase deficiency in female patients with congenital lactic acidemia. *J Inher Metab Dis* 1995;18:534–46.
- [12] Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukuyama R, et al. Endothelial dysfunction in MELAS was improved by L-arginine supplementation. *Neurology* 2006;66:1766–9.
- [13] Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. *Neurology* 2006;66:324–30.
- [14] Miller JP, Oldendorf WH. Regional kinetic constants for blood-brain barrier pyruvic acid transport in conscious rats by the monocarboxylic acid carrier. *J Neurochem* 1986;46:1412–6.
- [15] Long LH, Halliwell B. Artefacts in cell culture: pyruvate as a scavenger of hydrogen peroxide generated by ascorbate or epigallocatechin gallate in cell culture media. *Biochem Biophys Res Commun* 2009;388:700–4.
- [16] Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. *Lancet* 1999;353:1321–3.
- [17] Mallet RT, Sun J, Knott EM, Sharma AB, Olivencia-Yurvati AH. Metabolic cardioprotection by pyruvate: recent progress. *Exp Biol Med* 2005;230:435–43.
- [18] Sharma AB, Barlow MA, Yang S-H, Simpkins JW, Mallet RT. Pyruvate enhances neurological recovery following cardiopulmonary arrest and resuscitation. *Resuscitation* 2008;76:108–19.



MELAS: A nationwide prospective cohort study of 96 patients in Japan[☆]

Shuichi Yatsuga^{a,d}, Nataliya Povalko^a, Junko Nishioka^a, Koju Katayama^a, Noriko Kakimoto^a, Toyojiro Matsuishi^a, Tatsuyuki Kakuma^b, Yasutoshi Koga^{a,*} and Taro Matsuoka for MELAS Study Group in Japan^c

^a Department of Pediatrics and Child Health, Kurume University Graduate School of Medicine, Kurume, Japan

^b Department of Biostatistics, Kurume University Graduate School of Medicine, Kurume, Japan

^c MELAS study group in Japan

^d Research Program of Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland

ARTICLE INFO

Article history:

Received 30 January 2011

Accepted 21 March 2011

Available online 2 April 2011

Keywords:

Prevalence

MELAS

Cohort study

Natural course

Survival curve

Severity of disease

ABSTRACT

Background: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (OMIM 540000) is the most dominant subtype of mitochondrial myopathy. The aim of this study was to determine the prevalence, natural course, and severity of MELAS.

Methods: A prospective cohort study of 96 Japanese patients with MELAS was followed between June 2003 and April 2008. Patients with MELAS were identified and enrolled based on questionnaires administered to neurologists in Japan. MELAS was defined using the Japanese diagnostic criteria for MELAS. Two follow-up questionnaires were administered to neurologists managing MELAS patients at an interval of 5 years.

Results: A prevalence of at least 0.58 (95% confidential interval (CI), 0.54–0.62)/100,000 was calculated for mitochondrial myopathy, whereas the prevalence of MELAS was 0.18 (95%CI, 0.02–0.34)/100,000 in the total population. MELAS patients were divided into two sub-groups: juvenile form and adult form. Stroke-like episodes, seizure and headache were the most frequent symptoms seen in both forms of MELAS. Short stature was significantly more frequent in the juvenile form, whereas hearing loss, cortical blindness and diabetes mellitus were significantly more frequent in the adult form. According to the Japanese mitochondrial disease rating scale, MELAS patients showed rapidly increasing scores (mean \pm standard deviation, 12.8 ± 8.7) within 5 years from onset of the disease. According to a Kaplan–Meier analysis, the juvenile form was associated with a higher risk of death than the adult form (hazard ratio, 3.29; 95%CI, 1.32–8.20; $p = 0.0105$).

Conclusions and General Significance: We confirmed that MELAS shows a rapid degenerative progression within a 5-year interval and that this occurs in both the juvenile and the adult forms of MELAS and follows different natural courses. This article is part of a Special Issue entitled: Biochemistry of Mitochondria.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Mitochondrial dysfunction increases the risk of developing various human diseases, including degenerative neuromuscular disorders, diabetic or metabolic conditions, and cancer; it also affects the aging process [1]. The classical clinical entity in this category is the so-called mitochondrial myopathy, in which mitochondrial dysfunction is caused by mitochondrial or nuclear genetic abnormalities. The

disease, which encompasses mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) (OMIM 540000), is characterized by the early onset of stroke-like episodes and was first described by Pavlakis and colleagues in 1984 [2]; it is thought to be the most dominant subtype of mitochondrial dysfunction. At least 39 distinct mitochondrial DNA mutations have been associated with MELAS [3]; however, approximately 80% of MELAS patients have an A3243G mutation in the mitochondrial tRNA^{Leu(UUR)} gene (OMIM 590050) [4] and [5]. Because this mutation was also found to be a major genetic abnormality in diabetes mellitus, it may be a particularly common genetic variant in human populations [6]. Although more than 26 years have passed since the clinical and pathological definition of MELAS, there are few reports on its prevalence and epidemiology, and no reports exist on the natural course, survival rate or severity of the disease in a cohort study, meta-analysis, or nationwide survey [7] and [8]. In this study, we determined the prevalence, clinical symptoms, natural course, severity, and survival rate of MELAS patients in a nationwide Japanese

Abbreviations: JMDS, Japanese mitochondrial disease rating scale; NPMDs, Newcastle pediatric mitochondrial disease scale; NMDAS, Newcastle mitochondrial disease adult scale

[☆] This article is part of a Special Issue entitled: Biochemistry of Mitochondria.

* Corresponding author. Department of Pediatrics and Child Health, Kurume University School of Medicine, 67 Asahi-Machi, Kurume City, Fukuoka 30–0011, Japan. Tel.: +81 942 31 7565; fax: +81 942 38 1792.

E-mail address: yasukoga@med.kurume-u.ac.jp (Y. Koga).

cohort study. Additionally, we also evaluated the clinical rating scale that may be a very useful tool for the assessment of efficacy of therapeutic approach for mitochondrial myopathy.

2. Materials and methods

2.1. Study design, patients, and data collection for the Japanese cohort study

The cohort study was performed using questionnaires. To determine the prevalence of mitochondrial myopathies throughout the country, the first questionnaire was mailed in 2001 to 2236 neurology departments within Japan (1474 departments with pediatric neurologists and 762 departments with adult neurologists, including governmental, public, private and university hospitals with 50 beds or more). Patients' medical records were evaluated using MELAS diagnostic criteria (Table 1) and adequately screened. In 2003, after compiling the results of the first questionnaire, we mailed a second questionnaire to the neurologists who had examined MELAS patients in 2001. In 2008, we mailed a third questionnaire to the same group of neurologists. The second and third questionnaires included a Japanese mitochondrial disease rating scale (JMDS) (Supplemental Table 1). Relevant information from the medical records of eligible patients was transcribed onto case report forms by neurologists, who were later interviewed by telephone if ambiguous data or unsatisfactory descriptions were found in the case report forms. Detailed documentation of the patients' clinical status was compiled by the same neurologists. The case report form was originally constructed according to the JMDS and was updated whenever the scores were altered. Written informed consent was obtained from the patients or their legal guardians. The study protocol was approved by the Institutional Review Board (Kurume University #9715).

2.2. Diagnostic criteria for MELAS

The nationwide survey of MELAS in this study is based on the definitive diagnosis of MELAS presented in Table 1.

Table 1
Diagnostic criteria for MELAS (MELAS study committee in Japan).

Category A. Clinical findings of stroke-like episodes

1. Headache with vomiting
2. Seizure
3. Hemiplegia
4. Cortical blindness or hemianopsia
5. Acute focal lesion observed via brain imaging^a

Category B. Evidence of mitochondrial dysfunction

1. High lactate levels in plasma and/or cerebral spinal fluid or deficiency of mitochondrial-related enzyme activities^b
2. Mitochondrial abnormalities in muscle biopsy^c
3. Definitive gene mutation related to MELAS^d

Definitive MELAS

Two items of Category A and two items of Category B (four items or more)

Suspicion of MELAS

One item of Category A and two items of Category B (at least three items)

^a Focal brain abnormalities in CT and/or MRI.

^b 2 mmol/L (18mg/dl) or more lactate in plasma at rest or in cerebral spinal fluid and/or deficiency of electron transport chain enzyme, pyruvate-related, TCA cycle-related enzymes or lipid metabolism-related enzymes in somatic cells (desirable for muscle cells).

^c RRF (ragged-red fiber) in modified Gomori's trichrome stain and/or SSV (strongly SDH-reactive blood vessels) in succinate dehydrogenase stain, cytochrome c oxidase-deficient fibers or abnormal mitochondria in electron microscopy.

^d Definitive mitochondrial gene mutations reported in the literature (G583A, G1642A, G1644A, A3243G, A3243T, A3252G, C3256T, A3260G, T3271C, T3291C, G3481A, G3697A, T3949C, G4332A, G5521A, A5814G, G7023A, T7512C, A8296G, T8316C, T9957C, A12299C, A12770G, G13042A, A13084T, G13513A, A13514G, A13528G, and G14453A) as of 2010 [3].

2.3. Japanese Mitochondrial Disease Rating Scale (JMDS)

We prospectively analyzed the clinical progress of MELAS using the JMDS (Supplementary Table 1), which was revised following the European NeuroMuscular Conference (ENMC) in 2003 [9]. The second and the third questionnaires were also based on the JMDS and enabled longitudinal analysis of disease progression. We established a rating score for each patient in 2003 and 2008, and these values were used to analyze the clinical severity of MELAS.

2.4. Statistical analysis

Demographic and clinical data for the juvenile and adult forms of MELAS were summarized using descriptive statistics. An unpaired *t*-test was used to test for any differences in the death rates of juvenile and adult forms. Differences between the juvenile and adult forms in the symptoms at onset and throughout the entire follow-up period were evaluated by chi-square tests or Fisher's exacts test when the criteria for the chi-square test were not fulfilled. Alterations in the JMDS scores between 2003 and 2008 were evaluated using unpaired *t*-tests alone or combined with a Welch correction when variances were significantly different. Survival rates were compared between juvenile and adult forms using the log-rank test. Statistical analyses were performed with the SPSS 11.0 J software package for Windows. $p < 0.05$ was considered statistically significant.

3. Results

3.1. Questionnaire responses from the Japanese cohort

We received 1051 responses to the first questionnaire (total 47.0% response rate, 1051/2236); among them, 756 were from pediatric neurology departments (51.3% of responses) and 295 were from adult neurology departments (38.7% of responses). We identified 741 patients with mitochondrial myopathies and of these, 233 were MELAS patients (31.4% of total mitochondrial myopathy patients, 233/741), as described by 105 pediatric neurologists and 29 adult neurologists. We received 64 responses to the second questionnaire (total 47.8% response rate, 64/134): 36 from pediatric neurologists (34.3% response rate, 36/105) and 28 from adult neurologists (96.6% response rate, 28/29). We received 64 responses to the third questionnaire (100% response rate, 64/64); only 96 MELAS patients completed the 5-year cohort study.

3.2. Prevalence of MELAS in Japan

We found 741 cases of mitochondrial myopathy in our cohort study. Based on the MELAS diagnostic criteria (Table 1), we found 233 MELAS patients (juvenile/adult = 111/122) among the Japanese population of approximately 127,434,000 (approximately 22,275,000 under 18 years of age and approximately 105,159,000 over 18 years of age, adult form, according to census data from 2001). The prevalence of mitochondrial myopathy in Japan is therefore at least 0.58 (95% confidence interval (CI), 0.54–0.62)/100,000 in the total population. The prevalence of MELAS is at least 0.18 (95%CI, 0.17–0.19)/100,000 in the total population, 0.50 (95%CI, 0.41–0.59)/100,000 in children under 18 years of age, and 0.12 (95%CI, 0.10–0.14)/100,000 in the population over 18 years of age.

3.3. Demographic and pathological findings of MELAS in the cohort study

Our cohort study included 96 MELAS patients who were followed prospectively for 5 years. A histogram and a density plot showing the various ages of onset in MELAS in these patients indicate an approximately bimodal distribution (Fig. 1). We therefore divided the MELAS patients into two sub-groups to determine whether MELAS




Fig. 1. Histogram detailing age of onset. A histogram and density plot of the various ages of MELAS onset is shown. In total, 96 Japanese patients were identified as having definitive MELAS as determined by diagnostic criteria (Table 1). Given the approximately bimodal distribution of patient age, MELAS patients were divided into two subgroups by the age of onset. Patients with an age of onset less than 18 years old were defined as having the juvenile form of MELAS, and patients with an age of onset greater than 18 years old were defined as having the adult form of MELAS.

has different features depending on the age of onset. Patients with an age of onset under 18 years were defined as having the juvenile form of MELAS, whereas patients with an age of onset above 18 years were defined as having the adult form of MELAS. A summary of the indexed MELAS patients is shown (Table 2). The ages of onset, diagnosis, and death were determined for both juvenile and adult forms. During this study, 17 of the 20 deceased MELAS patients presented with the juvenile form. Causes of death were cardiac insufficiency (7), severe respiratory infection (6), multiple organ insufficiency (3), and unknown causes (4).

Seventy-eight patients received muscle biopsies and 71 patients (91.0%) showed positive findings, including ragged-red fibers (RRF), SDH strongly reactive blood vessels (SSV), or both. However, seven patients presented normal features in the muscle biopsy.

3.4. Symptoms at onset and during the entire course

We evaluated the symptoms at onset in 96 MELAS patients (Table 3). The first sign of any symptoms or events such as seizure, stroke-like episode, or severe headache, which were associated

Table 2
Demographic findings for MELAS cases.

	All form	Juvenile form	Adult
Patient ^b (male/female)	96 (52/44)	58 (35/23)	38 (17/21)
Age of onset, years ^a	17.7 ± 13.6	9.0 ± 4.7	32.2 ± 10.0
Age of diagnosis, years ^a	19.9 ± 13.5	11.0 ± 5.0	33.6 ± 10.6
Age of death, years ^a	18.8 ± 11.5	15.0 ± 7.9	40.0 ± 3.6
Death (%) ^{b,c}	20 (20.8 %)	17 (29.3 %)	3 (7.9 %)
Time from diagnosis to death ^a	7.3 ± 5.0	6.4 ± 4.5	10.2 ± 8.3
Positive family history ^b (%)	23 (24.0)	13 (22.4)	10 (26.3)
Muscle biopsy examination ^b	78	42	36
Positive findings ^b (%)	71 (91.0)	36 (85.7)	35 (97.2)
RRF ^b	56	24	32
SSV ^b	2	2	0
RRF + SSV ^b	13	10	3
A3243G mutation positive ^b (%)	75 (78.1)	46 (79.3)	29 (76.3)
Other mutation found in mtDNA ^b	4	4	0
Mutation not found ^b	17	8	9

^a Mean ± SD.

^b Number.

^c Death ratio was higher for the juvenile form than for the adult form ($p=0.0115$).

Table 3
Symptoms.

	Total (%) (n = 96)	Juvenile (%) (n = 58)	Adult (%) (n = 38)
Symptoms at onset			
Seizure	54/96 (56.3)	36/58 (62.1)	18/38 (47.4)
Stroke-like episode	53/96 (55.2)	29/58 (50.0)	24/38 (63.2)
Headache	48/96 (50.0)	27/58 (46.6)	21/38 (55.3)
Short stature ^a	46/96 (47.9)	35/58 (60.3)	11/38 (28.9)
Muscle weakness	36/96 (37.5)	26/58 (44.8)	10/38 (26.3)
General fatigue	30/96 (31.3)	20/58 (34.5)	10/38 (26.3)
Cortical blindness	26/96 (27.1)	15/58 (25.9)	11/38 (28.9)
Failure to thrive ^a	25/96 (26.0)	23/58 (39.7)	2/38 (5.3)
Vomiting/nausea	23/96 (24.0)	17/58 (29.3)	6/38 (15.8)
Hearing loss ^a	21/96 (21.9)	6/58 (10.3)	15/38 (39.5)
Unconsciousness	19/96 (19.8)	10/58 (17.2)	9/38 (23.7)
Teichopsia	18/96 (18.8)	12/58 (20.7)	6/38 (15.8)
Diabetes mellitus ^a	12/96 (12.5)	2/58 (3.4)	10/38 (26.3)
Symptoms in the entire course			
Stroke-like episode	81/96 (84.4)	49/58 (84.5)	32/38 (84.2)
Seizure	68/96 (70.8)	42/58 (72.4)	26/38 (68.4)
Short stature ^a	53/96 (55.2)	37/58 (63.8)	16/38 (42.1)
Headache	52/96 (54.2)	30/58 (51.7)	22/38 (57.9)
Cortical blindness ^a	43/96 (44.8)	21/58 (36.2)	22/38 (57.9)
Muscle weakness	40/96 (41.7)	27/58 (46.6)	13/38 (34.2)
General fatigue	38/96 (39.6)	26/58 (44.8)	12/38 (31.6)
Mental regression	38/96 (39.6)	20/58 (34.5)	18/38 (47.4)
Gait disturbance	37/96 (38.5)	23/58 (39.7)	14/38 (36.8)
Unconsciousness	36/96 (37.5)	20/58 (34.5)	16/38 (42.1)
Teichopsia	31/96 (32.3)	20/58 (34.5)	11/38 (28.9)
Cardiac dysfunction	29/96 (30.2)	18/58 (31.0)	11/38 (28.9)
Failure to thrive ^a	27/96 (28.1)	24/58 (41.4)	3/38 (7.9)
Speech disturbance	22/96 (22.9)	16/58 (27.6)	6/38 (15.8)
Memory loss	20/96 (20.8)	12/58 (20.7)	8/38 (21.1)
Diabetes mellitus ^a	20/96 (20.8)	5/58 (8.6)	15/38 (39.5)

^a Significant difference between juvenile and adult forms. $p < 0.05$ was considered statistically significant. At onset: short stature ($p=0.0026$), failure to thrive ($p=0.0001$), hearing loss ($p=0.0007$), diabetes mellitus ($p=0.0014$). During follow-up: short stature ($p=0.0366$), hearing loss ($p=0.0012$), cortical blindness ($p=0.0366$), failure to thrive ($p=0.0004$), diabetes mellitus ($p=0.0006$).

with a neuroimaging abnormality, was defined as the onset of MELAS. Symptoms at onset and during the entire course were similar as follows; seizure, stroke-like episode, and headache were the most frequent symptoms. Short stature and failure to thrive were significantly more prevalent in the juvenile form than in the adult form. However, hearing loss, diabetes mellitus and hemiplegia were significantly more frequent in the adult form than in the juvenile form.

3.5. Disease progression monitored with the JMDRS

MELAS was monitored in 2003 and 2008 with the JMDRS, which covers (1) activities of daily living, (2) motor functions, (3) special sensory functions, (4) endocrine functions, (5) cardiac functions, (6) renal functions, and (7) cognitive functions. Though JMDRS has not yet been validated, all MELAS patients had a significantly higher JMDRS score in 2008 than in 2003 (Table 4). Although no differences in the 2003 JMDRS scores were observed between the juvenile and adult forms, the 2008 scores revealed that the juvenile form was associated with a more aggressive deterioration than the adult form. The variation in scores between 2003 and 2008 was much larger in the juvenile form than in the adult form (Table 4).

3.6. Survival curve

Fig. 2 shows the Kaplan–Meier survival curve for MELAS patients. The log-rank analysis showed significant differences in survival between the juvenile and adult forms ($p=0.0105$). The juvenile

Table 4
Variations of the JMDRS score in the 5-year interval.

	2003	2008	p Value
Raw score (minimum = 0, maximum = 81)			
Total (n = 96)*	4.4 ± 3.2	16.1 ± 9.2	0.0001
Juvenile onset (n = 58)*	4.9 ± 3.0	19.1 ± 9.7 ^a	0.0001
Adult onset (n = 38)*	3.6 ± 3.5	11.5 ± 6.1 ^a	0.006
Score variances between 2003 and 2008			
Total (n = 96)*	11.8 ± 8.3		
Juvenile onset (n = 58)*	14.5 ± 8.8 ^b		
Adult onset (n = 38)*	7.8 ± 5.6 ^b		

^a p = 0.0001, raw scores between the juvenile and adult forms in 2008.

^b p = 0.0001, score variances between the juvenile and adult forms.

form had a higher rate of mortality than the adult form (hazard ratio, 3.29; 95%CI, 1.32–8.20).

4. Discussion

In this nationwide, multicenter, 5-year prospective Japanese cohort study, we determined the prevalence of mitochondrial myopathies such as Kearns Sayre syndrome (KSS)/progressive external ophthalmoplegia (PEO), Leigh syndrome, and MELAS. In our study, the prevalence of mitochondrial myopathy was at least 0.58/100,000 in the total population, with MELAS as the most common subtype (data not shown). Although the reported prevalence of mitochondrial disease varies depending on methodology, geography, ethnic group, and subject group, the population-based prevalence of mitochondrial disease risk was 9.18 to 12.48/100,000 in the total population of northeast England [10,11] and [12], 16.5/100,000 in the pediatric population of northeast England [10], 4.7 (95%CI, 2.8–7.6)/100,000 in the pediatric population of western Sweden [13], and 5.0 (95%CI, 4.0–6.2)/100,000 to 13.1/100,000 at birth in Victoria, Australia [14] and [15]. In general, epidemiological studies have estimated that the minimum prevalence of mitochondrial disease is 1/5000 in the general population [16]. The aforementioned prevalence estimates are approximately 10- to 34-fold higher than our estimate (0.58 (95%CI, 0.54–0.62)/100,000 in the total population).

This discrepancy can be explained partly by methodological differences. Because all previously reported prevalence data are based on estimations of risk of mitochondrial diseases extrapolated from the mutation or disease frequency in a limited population or region with regional mitochondrial research institutes or mitochon-




Fig. 2. MELAS survival curve. A Kaplan–Meier survival curve is shown. The dashed line indicates the juvenile form and the solid line indicates the adult form. The results of the log-rank analysis were significant. The juvenile form was associated with a higher risk of mortality than the adult form (hazard ratio, 3.29; 95%CI, 1.32–8.20).

drial specialists, these values are likely to overestimate the prevalence in the entire population. Whether carriers of pathogenic mitochondrial DNA develop severe mitochondrial disorders depends on the degree and distribution of the mutation in important somatic organs. Although all prevalence studies can contain methodological bias, the prevalence of mitochondrial myopathy should be confirmed by a meta-analysis or nationwide cohort studies in other countries. The discrepancy between our prevalence estimate and previously reported data might also be attributable to a number of additional factors. First, we might have missed some patients due to the imperfect response rate (47%), even though our study included almost all of the main hospitals and institutes in Japan. There was no tendency with respect to region for the lack of responses. However, the response rate for the second questionnaire was significantly different between pediatric and adult neurologists. Pediatric neurologists may not have examined MELAS patients in 2003 although they had examined MELAS patients in 2001; because juvenile MELAS develops at a faster rate than adult MELAS, patients may have died or been referred to an inpatient hospital during 2-year interval. All non-responsive hospitals had less than 300 beds. Generally in Japan, MELAS that is very rare and multi-systemic diseases are monitored in large hospitals that have many departments and beds. Second, it is possible that the mitochondrial myopathies may have been misdiagnosed due to their rarity. Finally, given that most of the prior reports described Caucasian populations, it is possible that the disparity may derive from racial differences. In 2010, the Ministry of Health, Welfare and Labour, Japan has newly approved the mitochondrial myopathy as a supported disorders for their medical expenses, and started to collect the application for such privilege in entire Japan. In above situation, only 100 applications have been collected, to date (personal communication). Because our first questionnaire is also including death case of mitochondrial myopathies, our result come from disease-based prevalence study may be more realistic date at least in Japan.

Because MELAS is the most dominant subtype of mitochondrial myopathy and has been associated with an A3243G mutation in the mitochondrial tRNA^{Leu(UUR)} gene, several studies have reported the prevalence of the A3243G mutation. The absolute prevalence of this mutation has been estimated to be as high as 1.41 (95%CI, 0.83–1.20)/100,000 individuals in northern England [12] and [17], 16.3 (95%CI, 11.3–21.4)/100,000 in the adult population of northern Finland [18], and 18.4 (95%CI, 10.9–29.1)/100,000 in the Finnish pediatric population [19]. With the exception of a report from Australia in a large Caucasian population that showed the highest prevalence of 236/100,000 [20], the prevalence of MELAS in Japan (0.18 (95%CI, 0.17–0.19)/100,000) seems to be quite reasonable, given the previously reported prevalence of the A3243G mutation. Because this mutation has been found in association with various clinical conditions, including subclinical asymptomatic carriers and patients with short stature, diabetes mellitus, migraine headache, PEO, MELAS, and/or Leigh syndrome with cardiomyopathy, only individuals whose mutation load in important organs is 50% or more may present with MELAS or a more severe phenotype [21]. Multiple medical problems, including various neurological, cardiological, endocrinological, gastroenterological, and psychiatric symptoms, were reported in 45 families with 45 MELAS patients and 78 carrier relatives in a regional cohort study in the USA [22]. Accordingly, the actual prevalence of the A3243G mutation in human populations may be much higher than previously thought, if we take into account not only the individuals who showed full symptoms of mitochondrial disorders, but also those who show minimal symptoms, even when they were not followed up at a hospital. Nevertheless, MELAS is a clinically and histopathologically defined entity, and the prevalence of MELAS (0.18/100,000 in the total population) in Japan is unlikely to change drastically given more information.

To identify the various symptoms associated with MELAS, we defined the diagnostic criteria for MELAS in Japanese patients. The diagnostic criteria were constructed on the basis of the information provided by Hirano [23] and Hirano and Pavlakis [7]. Category A contains clinical findings of stroke-like episodes, while category B contains evidence of mitochondrial dysfunction. We evaluated only 96 out of 233 MELAS patients. The other patients were excluded for the following reasons; 1) non-response, 2) failure to receive informed consent, 3) patients/neurologists moved to other regions, and 4) other unknown reasons.

According to our data, MELAS can be divided into two subgroups: juvenile and adult forms. This distinction is warranted because of an approximately bimodal distribution of the age of onset, different manifestations of MELAS symptoms in pediatric and adult patients, and differences in the progression of disease as monitored by JMDRS scores. The juvenile form is more severe than the adult form (Tables 2 and 3). No differences in family history were noted between these two forms. However, the juvenile form was associated with significantly higher mortality and a more rapid disease progression than the adult form. We believe that this discrepancy arises because (1) children require more energy to complete their development and maintain their physicality and (2) juvenile patients may have a higher mutation load in mitochondrial genes than in adult patients. Almost all patients with the adult form have a normal life until onset despite having some kind of mitochondrial dysfunction. Therefore, it appears that the adult form requires a longer time for significant symptoms to develop and for the disease to worsen. Because the juvenile form has a greater mutation load than the adult form, it can present more severe complications such as the cardiac and/or renal failure, and patients with the juvenile form are at increased risk of multiple organ failure. Patients with the adult form of MELAS are more likely to have diabetes mellitus and to have a more gradual disease progression. Given these differences in disease progression, our 5-year cohort study may not have provided sufficient time to identify the chronic negative effects of diabetes mellitus especially in the adult form.

Among the clinical symptoms at onset or during the entire course of the disease, seizure and headache were very common and associated with stroke-like episodes in both the juvenile and the adult form. However, of the symptoms present at onset, short stature and failure to thrive were significantly more common in the juvenile form than in the adult form. In contrast, patients with the adult form presented with symptoms such as diabetes mellitus and hearing loss significantly more often than patients with the juvenile form, perhaps because these symptoms are more chronic and maturity (age)-related and can be induced by the accumulation of abnormal mitochondria in low-turnover environments such as pancreatic beta-cells or hearing organs. Of the symptoms encountered during the entire course of the disease, stroke-like episodes were noted in more than 84% of juvenile and adult form patients. Seizure and headache, which are the main symptoms associated with stroke-like episodes, were also common in both juvenile and adult forms. Interestingly, hearing loss, cortical blindness and diabetes mellitus, which are not recognized as main symptoms, were seen significantly more often in the adult form than in the juvenile form. The symptoms listed in our study are consistent with those of previous reports, including the American cohort study [7,8] and [24], the Finnish cohort study [19], and the Japanese muscle biopsy registry of MELAS [5].

We used JMDRS scores to evaluate the progression of MELAS over a 5-year interval. The validated mitochondrial disease rating scale was published in 2006 [25] and [26]. This scale has four classifications, which are age group classification of 0–24 months, 2–11 years, and 12–18 years from the Newcastle pediatric mitochondrial disease scale (NPMDS) [25], and an adult age group classification from the Newcastle mitochondrial disease adult scale (NMDAS) [26]. We had to use the JMDRS although it had not yet been validated because this study started in 2001, and the rating scale was initially mailed to the

neurologists in 2003. Contents and indexed factors are similar between NPMDS, NMDAS, and JMDRS. However, NPMDS and NMDAS include contents from patient interviews. This feature is quite different between the Newcastle scales and the JMDRS. In all other respect, the JMDRS is thought to be a comprehensive, quantitative, reproducible, and sensitive monitoring system to detect the progression of disease severity in MELAS. We aimed to use and analyze JMDRS as a pilot study in the present work. According to this analysis, all MELAS patients (both juvenile and adult forms) showed an increased score and worsening of their condition during the 5-year interval. The progression of dysfunction in section 1 (activity of daily living), section 2 (motor activity) and section 7 (cognition and impairment) occurred more rapidly than that in other sections, and it was more pronounced in the juvenile form than in the adult form (data not shown). Patients with more rapidly increasing scores were more commonly found in the group with the juvenile form and had a higher risk of death than those with a more mild disease. This result indicates that the juvenile form progresses more rapidly and is more severe than the adult form. Despite the lack of validation, in this study the JMDRS produced findings that were consistent with a previous study [27] and we believe that the JMDRS is a useful scoring system that allows sensitive and reproducible monitoring of the progression of MELAS. In the future, we will more explicitly validate the JMDRS scoring system for MELAS.

In conclusion, given that no drugs have yet been approved for MELAS, we believe it is important to develop efficacious treatments for MELAS. L-arginine therapy, which is currently in development for MEALS [28], might be a promising drug for the future, and we believe that the results from this study will be helpful for the development of new therapeutic interventions aimed at MELAS.

5. Conclusions

We determined that MELAS occurs into two forms; adult and juvenile, and that the juvenile form is more severe than the adult form. Although our results may contain several biases, including limited information from neurologists, our data highlight new and important information for both pediatric and adult neurologists who are assessing MELAS patients. JMDRS is a useful scoring system for evaluating disease progression in MELAS.

Supplementary materials related to this article can be found online at doi:10.1016/j.bbagen.2011.03.015.

Acknowledgments

All coauthors have seen the manuscript and have reported no conflicts of interest (financial or nonfinancial) and any other pertinent financial information. This work was supported in part by grants #13670853 (Y.K.) and #16390308 (Y.K.) from the Ministry of Culture and Education in Japan, as well as #CCT-B-1803 (Y.K.) from Evidence-based Medicine, Ministry of Health, Labor and Welfare in Japan. S.Y. is a recipient of a post-doctoral fellowship from the Academy of Finland, the Center for International Mobility in Finland. N.P. is a recipient of a grant-in-aid for young investigators from the Heiwa Research Foundation in Japan.

The authors express thanks to the following investigators of the MELAS study group in Japan for participating in the nationwide cohort study and providing important information on MELAS patients: Drs. Hideki Hozen (Obihiro), Muneaki Matsuo (Saga), Atsushi Yamagishi (Takayama), Yasushi Otsuka (Toki), Shinji Saitoh (Sapporo), Takahiro Iizuka (Sagamihara), Tomoyuki Takano (Otsu), Shuji Hashiguchi (Yoshinogawa), Akihiko Ogata (Sapporo), Nobuya Fujita (Nagaoka), Kazuyuki Yotsumoto (Kagoshima), Ken Sakurai (Tokyo), Taro Matsuoka (Toyonaka), Megumi Nakanishi (Kahoku), Yukihiko Shikama (Kahoku), Kimihiko Yoshimura (Kochi), Takao Soda (Izumisano), Susumu Ito (Kita), Takuma Iwaki (Kita), Tetsuya Ito (Nagoya), Akira

Sudo (Sapporo), Hiroyuki Torisu (Fukuoka), Minako Kihara (Kyoto), Shuji Kishida (Tokyo), Akiko Ishii (Tsukuba), Kenji Fujishima (Tokyo), Hisashi Kawawaki (Osaka), Shin Okazaki (Osaka), Hiroyuki Watanabe (Nagaoka), Kazumasa Shindo (Chuo), Yasuhisa Toribe (Izumi), Yukiko Mogami (Izumi), Keiko Yanagihara (Izumi), Go Tajima (Hiroshima), Atsuko Noguchi (Akita), Etsuo Naito (Tokushima), Kazuhiro Oginoya (Sendai), Masataka Kitaguchi (Sakai), Sadayuki Nukina (Akashi), Kazutoshi Nakano (Tokyo), Yoshihide Sunada (Kurashiki), Hitoshi Sejima (Izumo), Yasumasa Ohyagi (Fukuoka), Muneichiro Sumi (Omura), Tomoaki Yuhi (Kitakyushu), Mitsue Fujita (Tsukuba), Yasuto Higashi (Himeji), Makoto Yoneda (Yoshida), Masanori Nakagawa (Kyoto), Ritsuko Shigemori (Matsuyama), and Hidee Arai (Chiba).

References

- [1] R.W. Taylor, D.M. Turnbull, Mitochondrial DNA mutations in human disease, *Nat. Rev. Genet.* 6 (2005) 389–402.
- [2] S.G. Pavlakis, P.C. Phillips, S. DiMauro, D.C. De Vivo, L.P. Rowland, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes: a distinctive clinical syndrome, *Ann. Neurol.* 16 (1984) 481–488.
- [3] S. DiMauro and M. Hirano, MELAS, R.A. Pagon, T.C. Bird, C.R. Dolan, K. Stephens and editors, Seattle (WA), University of Washington Seattle, *Gene reviews* [Internet; <http://www.ncbi.nlm.nih.gov/books/NBK1233/>] (1993), updated 2010 Oct 14.
- [4] Y. Goto, I. Nonaka, A. Horai, A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies, *Nature* 348 (1990) 651–653.
- [5] Y. Goto, S. Horai, T. Matsuoka, Y. Koga, K. Nihei, M. Kobayashi, I. Nonaka, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation, *Neurology* 42 (1992) 545–550.
- [6] J.M. van den Ouweland, H.H. Lemkes, K.D. Gerbitz, J.A. Maassen, Maternally inherited diabetes and deafness (MIDD): a distinct subform of diabetes associated with a mitochondrial tRNA(Leu)(UUR) gene point mutation, *Muscle Nerve* 3 (1995) S124–130.
- [7] M. Hirano, S.G. Pavlakis, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): current concepts, *J. Child Neurol.* 9 (1994) 4–13.
- [8] D.M. Sproul, P. Kaufmann, Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes, basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome, *Ann. N.Y. Acad. Sci.* 1143 (2008) 133–158.
- [9] P.F. Chinnery, L.A. Bindoff, 116th ENMC international workshop: the treatment of mitochondrial disorders, 14th–16th March 2003, Naarden, The Netherlands, *Neuromuscul. Disord.* 13 (2003) 757–764.
- [10] A.M. Schaefer, R. McFarland, E.L. Blakely, L. He, R.G. Whittaker, R.W. Taylor, P.F. Chinnery, D.M. Turnbull, Prevalence of mitochondrial DNA disease in adults, *Ann. Neurol.* 63 (2008) 35–39.
- [11] A.M. Schaefer, R.W. Taylor, D.M. Turnbull, P.F. Chinnery, The epidemiology of mitochondrial disorders—past, present and future, *Bioch. Biophys. Acta* BBA Bioenerg. 1659 (2004) 115–120.
- [12] P.F. Chinnery, M.A. Johnson, T.M. Wardell, R. Singh-Kler, C. Hayes, D.T. Brown, R.W. Taylor, L.A. Bindoff, D.M. Turnbull, The epidemiology of pathogenic mitochondrial DNA mutations, *Ann. Neurol.* 48 (2000) 188–193.
- [13] N. Darin, A. Oldfors, A.R. Moslemi, E. Holme, M. Tulinius, The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities, *Ann. Neurol.* 49 (2001) 377–383.
- [14] D. Skladal, J. Halliday, D.R. Thorburn, Minimum birth prevalence of mitochondrial respiratory chain disorders in children, *Brain* 126 (2003) 1905–1912.
- [15] D.R. Thorburn, Mitochondrial disorders: prevalence, myths and advances, *J. Inher. Metab. Dis.* 27 (2004) 349–362.
- [16] H.R. Elliott, D.C. Samuels, J.A. Eden, C.L. Relton, P.F. Chinnery, Pathogenic mitochondrial DNA mutations are common in the general population, *Am. J. Hum. Genet.* 83 (2008) 254–260.
- [17] P.F. Chinnery, D.M. Turnbull, Epidemiology and treatment of mitochondrial disorders, *Am. J. Med. Genet.* 106 (2001) 94–101.
- [18] K. Majamaa, J.S. Moilanen, S. Uimonen, A.M. Remes, P.I. Salmela, M. Kärppää, K.A. Majamaa-Voltti, H. Rusanen, M. Sorri, K.J. Peuhkurinen, I.E. Hassinen, Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: prevalence of the mutation in an adult population, *Am. J. Hum. Gen.* 63 (1998) 447–454.
- [19] J. Uusimaa, J.S. Moilanen, L. Vainionpää, P. Tapanainen, P. Lindholm, M. Nuutinen, T. Löppönen, E. Mäki-Torkko, H. Rantala, K. Majamaa, Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children, *Ann. Neurol.* 62 (2007) 278–287.
- [20] N. Manwaring, M.M. Jones, J.J. Wang, E. Roethchchina, C. Howard, P. Mitchell, C.M. Sue, Population prevalence of the MELAS A3243G mutation, *Mitochondrion* 7 (2007) 230–233.
- [21] Y. Koga, Y. Akita, N. Takane, Y. Sato, H. Kato, Heterogeneous presentation in A3243G mutation in the mitochondrial tRNA(Leu)(UUR) gene, *Arch. Dis. Child.* 82 (2000) 407–411.
- [22] P. Kaufmann, K. Engelstad, Y. Wei, R. Kulikova, M. Oskoui, V. Battista, D.Y. Koenigsberger, J.M. Pascual, M. Sano, M. Hirano, S. DiMauro, D.C. Shungu, X. Mao, D.C. DeVivo, Protean phenotypic features of the A3243G mitochondrial DNA mutation, *Arch. Neurol.* 66 (2009) 85–91.
- [23] M. Hirano, E. Ricci, M.R. Koenigsberger, R. Defendini, S.G. Pavlakis, D.C. DeVivo, S. Diauro, L.P. Rowland, Melas: an original case and clinical criteria for diagnosis, *Neuromuscul. Disord.* 2 (1992) 125–135.
- [24] D.M. Sproule, P. Kaufmann, K. Engelstad, T.J. Starc, A.J. Hordof, D.C. De Vivo, Wolff–Parkinson–White syndrome in patients with MELAS, *Arch. Neurol.* 64 (2007) 1625–1627.
- [25] C. Phoenix, A.M. Schaefer, J.L. Elson, E. Morava, M. Bugiani, G. Uziel, J.A. Smeitink, D.M. Turnbull, R. McFarland, A scale to monitor progression and treatment of mitochondrial disease in children, *Neuromuscul. Disord.* 16 (2006) 814–820.
- [26] A.M. Schaefer, C. Phoenix, J.L. Elson, R. McFarland, P.F. Chinnery, D.M. Turnbull, Mitochondrial disease in adults: A scale to monitor progression and treatment, *Neurology* 66 (2006) 1932–1934.
- [27] D. Skladal, V. Sudmeier, S. Konstantopoulou, S. Stöckler-Ipsiroglu, B. Plecko-Startinig, G. Bernert, J. Zeman, W. Sperl, The spectrum of mitochondrial disease in 75 pediatric patients, *Clin. Pediatr.* 42 (2003) 703–710.
- [28] Y. Koga, N. Povalko, J. Nishioka, K. Katayama, N. Kakimoto, T. Matsuishi, MELAS and L-arginine therapy: pathophysiology of stroke-like episodes, *Ann. NY Acad. Sci.* 1201 (2010) 104–110.

Evaluation of Systemic Redox States in Patients Carrying the MELAS A3243G Mutation in Mitochondrial DNA

Masamichi Ikawa^a Kenichiro Arakawa^b Tadanori Hamano^a Miwako Nagata^c
Yasunari Nakamoto^a Masaru Kuriyama^a Yasutoshi Koga^d Makoto Yoneda^a

^aSecond Department of Internal Medicine, and ^bDepartment of Cardiology, Faculty of Medical Sciences, University of Fukui, and ^cDepartment of Neurology, Nakamura Hospital, Fukui, and ^dDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan

Key Words

MELAS · A3243G mutation · Mitochondrial DNA · Oxidative stress · Antioxidant activity · Redox states · d-ROMs test · BAP test

Abstract

Background/Aims: To clarify the change of systemic redox states in patients carrying the A3243G mutation in mitochondrial DNA (A3243G), we evaluated oxidative stress and antioxidant activity in the serum of patients. **Methods:** Oxidative stress and antioxidant activity in the serum samples obtained from 14 patients carrying A3243G and from 34 healthy controls were analyzed using the diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests, respectively. **Results:** The mean d-ROMs level of all patients was significantly greater than that of the controls ($p < 0.005$), and the mean BAP/d-ROMs ratio of all patients was significantly lower than that of the controls ($p < 0.02$). In the patients with a history of stroke-like episodes ($n = 10$), both mean d-ROMs and BAP levels were increased compared with those of the controls (both $p < 0.01$). The mean BAP level of the patients without a history of stroke-like episodes ($n = 4$) was significantly decreased compared with that of the controls ($p < 0.001$), but the mean d-

ROMs levels were not significantly different. **Conclusion:** d-ROMs and BAP tests indicated that patients carrying A3243G are always exposed to underlying oxidative stress, even at a remission state of stroke-like episodes.

Copyright © 2012 S. Karger AG, Basel

Introduction

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome is the most common type of mitochondrial disease, and is mainly caused by an A-to-G transition mutation at nucleotide position 3243 (A3243G) in mitochondrial DNA (mtDNA) [1]. MELAS is characterized by stroke-like episodes that occur repeatedly and provoke neurological symptoms (e.g. headache, epilepsy, hemiparesis, and dementia) due to 'stroke-like' brain lesions [2]. In other words, stroke-like episodes are diagnostic symptoms of MELAS, and are crucial factors determining the prognosis of patients with this syndrome [2].

In addition, A3243G is responsible for not only stroke-like episodes but also mitochondrial cardiomyopathy or diabetes mellitus (DM) [1, 3–6]. Conversely, some patients carrying A3243G present with typical MELAS syn-

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2012 S. Karger AG, Basel
0014-3022/12/0674-0232\$38.00/0

Accessible online at:
www.karger.com/ene

Makoto Yoneda, MD, PhD
Second Department of Internal Medicine
Faculty of Medical Sciences, University of Fukui
23-3 Shimoaiduki, Matsuoka, Eihei-ji-cho, Fukui 910-1193 (Japan)
Tel. +81 776 61 8351, E-Mail myoneda@u-fukui.ac.jp

Table 1. Demographic characteristics of patients and controls

Subject	Patients			Normal controls
	all	'stroke type'	'non-stroke type'	
Number	14	10	4	34
Gender (males/females)	7/7	5/5	2/2	20/14
Mean age at examination, years	32.1 ± 14.7	27.8 ± 12.5	42.8 ± 15.8	34.6 ± 7.4
Clinical features				
Stroke-like episodes, n	10	10	0	0
Cardiomyopathy, n	6	2	4	0
Diabetes, n	3	0	3	0
Under antioxidant therapy, n	11	10	1	0

Values are mean ± SD.

dromes with stroke-like episodes, and others present with only cardiomyopathy or DM without stroke-like episodes. However, the pathophysiological difference of phenotypes between the presence and absence of stroke-like episodes in patients carrying A3243G remains obscure.

Recent studies using cells cultured *in vitro* demonstrated increased oxidative stress in cells with impaired mitochondria due to A3243G [7–10]. Oxidative stress is provoked by reactive oxygen species (ROS) generation exceeding antioxidant defenses, such as manganese superoxide dismutase and glutathione peroxidase, and damages nucleic acids, proteins and lipids, which leads to cellular dysfunction. Indeed, previous pathological or imaging studies demonstrated enhanced regional oxidative stress in lesions of both stroke-like episodes and cardiomyopathy in patients carrying A3243G [11–13]. Therefore, there is a high possibility that oxidative stress participates in the pathogenesis caused by A3243G, and influences the phenotypic diversity. In other words, redox (reduction-oxidation) states should be evaluated in patients carrying A3243G both with and without a history of stroke-like episodes to clarify the role of oxidative stress in the emergence of stroke-like episodes.

To perform such an investigation, a rapid and reliable method of evaluating redox states in patients carrying A3243G is needed. Direct measurement of oxidative stress and antioxidant activity in living humans has been difficult; redox states have thus not been clearly evaluated in patients carrying A3243G to date. Recently, the diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests have been used to evaluate redox states in serum. The d-ROMs level reflects

the intensity of oxidative stress, and the BAP level indicates the activity of endogenous antioxidants [14, 15]. Their effectiveness as clinical markers has been reported in various diseases [16–22]. We evaluated redox states in fresh serum of both patients carrying A3243G and healthy volunteers using d-ROMs and BAP tests, and clarified the change of redox states due to A3243G and the pathophysiological difference in phenotypes with or without stroke-like episodes.

Subjects and Methods

Subjects

Fourteen Japanese patients (7 men and 7 women; mean age 32.1 ± 14.7 years) carrying A3243G were recruited at the University of Fukui Hospital, Fukui, and at the Kurume University Hospital, Fukuoka, Japan (table 1). Patients were classified by the presence or absence of stroke-like episodes into 'stroke type' and 'non-stroke type'. Ten patients with a history of stroke-like episodes were categorized as 'stroke type', and the other 4 patients who presented with mainly cardiomyopathy without a history of stroke-like episodes were categorized as 'non-stroke type'. Eleven patients were treated by antioxidant therapy such as coenzyme Q₁₀ (CoQ₁₀; daily dose 30–90 mg) and/or vitamin E (daily dose 100 mg) administration; 10 of these patients were 'stroke type', and the other patient was 'non-stroke type'. Eight patients categorized as 'stroke type' were also treated with an oral administration of L-arginine (daily dose 14–21 g). All patients were in remission, free from exacerbation of symptoms or acute stroke-like episodes, when they were examined. Functional status was evaluated using the performance status rating (mean rating 1.3 ± 1.0). In 'stroke type' patients, the mean age of the first stroke-like episode was 21.1 ± 15.2 years, and the mean duration between the examination and the last stroke-like episode was 14.2 ± 9.2 months. 'Stroke type' patients had headaches and/or vomiting on average twice a month, but almost none had convulsions. Thirty-four Jap-




Fig. 1. Scatter plots portraying the levels of d-ROMs (a) and BAP (b) and BAP/d-ROMs ratios (c) in all the patients and controls. Circles and triangles correspond to the patients with and without antioxidant administration, respectively. In addition, closed and

open diagrams correspond to the 'stroke type' patients and 'non-stroke type' patients, respectively. * $p < 0.02$, ** $p < 0.005$, according to the two-tailed Mann-Whitney U test. Bars indicate mean \pm SD.

ane healthy volunteers (20 men and 14 women; mean age 34.6 ± 7.4 years) were also recruited as normal controls from the local community (table 1). This study was approved by the Ethics Committee of the University of Fukui. All subjects provided written informed consent to participate in the study.

Measurement of Oxidative Stress Levels

The oxidative stress levels were evaluated by measuring the quantity of hydroperoxides (R-OOH) in fresh serum samples using the d-ROMs test with the Free Radical Analytical System 4 (FRAS4^R; H&D srl, Parma, Italy) automatically [14]. Blood sampling was performed at fasting and at rest. Hydroperoxides consist of dehydrogenized and peroxidized proteins, lipids and fatty acids produced by ROS. In the d-ROMs test, hydroperoxides are turned to radicals by the Fenton reaction in an acid medium, and these generated radicals oxidize *N,N*-diethyl-*para*-phenylenediamine (DEPPD). Oxidized DEPPD quantity is determined by an absorbency measurement (white light 505 nm). The sequence of these methods is automated, and oxidative stress levels can be evaluated easily and quickly. The values are expressed as U. Carr, where 1 U. Carr corresponds to $0.8 \text{ mg/l H}_2\text{O}_2$.

Measurement of Antioxidant Activity Levels

The antioxidant activity levels were evaluated by measuring the quantity of molecules with antioxidative potency in fresh serum samples using the BAP test in the FRAS4^R automatically [15, 17]. Blood sampling was performed at fasting and at rest. In the BAP test, serum molecules with antioxidative potency reduce and decompose compounds of ferric chloride (FeCl_3) and thiocyanate derivative (AT) to FeCl_2 and free AT. Free AT is achromatized and dissociates from compounds, and is quantified by an absorbency

measurement (white light 505 nm). The sequence of these methods is automated, and antioxidant activity levels can be evaluated easily and quickly. The results are expressed as $\mu\text{mol/l}$.

Statistical Analysis

The BAP-to-d-ROMs ratio (BAP/d-ROMs ratio) was calculated from the ratio of the BAP levels and d-ROMs levels for each subject. Data are presented as means \pm standard deviations (SD). The resultant differences between normal controls and all patients were analyzed by means of a two-tailed Mann-Whitney U test. Since the subject number of each group was small, a non-parametric Kruskal-Wallis test was used for multiple data comparison and a post hoc Dunn test was performed to evaluate differences among normal controls, 'stroke type' patients and 'non-stroke type' patients. All statistical analyses were performed in SPSS Statistics Version 17.0 (SPSS Japan Inc., Tokyo, Japan), and $p < 0.05$ was considered significant.

Results

The levels of serum d-ROMs and BAP, and BAP/d-ROMs ratios of all the patients and controls are shown in figure 1, and those of the 'stroke type' patients, 'non-stroke type' patients and controls are shown in figure 2. The mean age of each group demonstrated no significant differences.

The mean d-ROMs level of all patients (332.6 ± 110.7 U. Carr) was significantly higher than that of the controls




Fig. 2. The mean d-ROMs (a) and BAP (b) levels and mean BAP/d-ROMs ratio (c) in the 'stroke type' patients (black), 'non-stroke type' patients (grey) and controls (white). *** $p < 0.01$, **** $p < 0.001$, according to the Dunn test. Bars indicate mean \pm SD.

(259.1 ± 42.0 U. Carr; $p < 0.005$) (fig. 1a). In particular, the mean d-ROMs level of the 'stroke type' patients (361.0 ± 119.6 U. Carr) was significantly greater than that of the controls ($p < 0.01$) (fig. 2a). Meanwhile, the mean d-ROMs level of 'non-stroke type' patients (261.5 ± 28.0 U. Carr) demonstrated no significant differences compared with those of the controls and 'stroke type' patients (fig. 2a).

The mean BAP level of all patients ($2,258.9 \pm 517.7$ $\mu\text{mol/l}$) was not significantly different compared with that of the controls ($2,057.6 \pm 149.5$ $\mu\text{mol/l}$) (fig. 1b). However, compared with the controls, 'stroke type' patients ($2,428.9 \pm 523.1$ $\mu\text{mol/l}$) demonstrated significantly high BAP levels ($p < 0.01$), and 'non-stroke type' patients ($1,834.0 \pm 59.2$ $\mu\text{mol/l}$) demonstrated significantly low BAP levels ($p < 0.001$) (fig. 2b). There was no significant difference between 'stroke type' patients and 'non-stroke type' patients in terms of the mean BAP levels.

The mean BAP/d-ROMs ratio of all patients (7.87 ± 5.05) was significantly lower than that of the controls (8.13 ± 1.30 ; $p < 0.02$) (fig. 1c). However, there were no significant differences among the controls and patient groups (fig. 2c).

There was no relationship between the functional status evaluated by performance status rating and the d-ROMs level or BAP level or BAP/d-ROMs ratio.

Discussion

In the present study, the d-ROMs and BAP tests were applied to evaluate the redox states in serum of patients carrying A3243G. These tests demonstrated that oxidative stress represented by the d-ROMs levels was increased and redox balance represented by the BAP/d-ROMs ratios was decreased (tendency for oxidation) in the patients compared with those of the controls (fig. 1). These findings suggested that an imbalance of redox states due to mitochondrial dysfunction affects the pathogenesis in patients carrying A3243G.

In the 'stroke type' patients in particular, both d-ROMs levels (oxidative stress) and BAP levels (antioxidant activity) were increased compared with those of the controls (fig. 2a, b). In vitro studies previously demonstrated that A3243G enhances ROS generation leading to oxidative stress [7–10], and enhanced oxidative stress is proportional to mitochondrial dysfunction [7, 23]. In the present study, all of the 'stroke type' patients have been treated with antioxidants, and 8 out of 10 patients were also treated with an oral administration of L-arginine. Although serum antioxidant activity may be increased by antioxidants and L-arginine therapy, serum oxidative stress was still increased in 'stroke type' patients. Increased oxidative stress even with increased antioxidant activity suggested a severe deterioration of mitochondrial function in patients with a history of stroke-like epi-

sodes, and that oxidative stress plays a crucial role not only in the brain lesions of stroke-like episodes [11, 12] but also systemically in these patients. In other words, a history of stroke-like episodes indicates that patients who have these episodes are exposed to underlying oxidative stress.

In the 'non-stroke type' patients, the mean d-ROMs level (oxidative stress) was not significantly different compared with that of the controls (fig. 2a). Meanwhile, the BAP levels (antioxidant activity) were significantly decreased (fig. 2b). Only 1 of 4 patients was treated with antioxidants, and antioxidant therapy may not affect antioxidant activity in 'non-stroke type' patients. These findings may reflect that antioxidants are consumed in order to prevent increase of oxidative stress in these patients. In addition, the difference of profiles in redox states between 'stroke type' and 'non-stroke type' suggested phenotypic diversity in patients carrying A3243G.

In the present study, we presented redox states in the serum of patients carrying A3243G using the d-ROMs and BAP tests. Rapid evaluation of redox states in serum has been difficult to date. To assay oxidative stress in serum, the spin trap method using electron spin resonance (ESR) has been the most reliable method [24]. However, performing ESR is cumbersome, thus it is difficult to apply this method in clinical practice. The d-ROMs test can evaluate oxidative stress in serum by measuring oxides due to hydroperoxides, and this test has been validated by ESR [25]. Likewise, each endogenous antioxidant can be measured, but there has been no method estimating the whole activity of endogenous antioxidants in serum to date. The BAP test provides a reliable indicator of the antioxidant activity in serum by measuring the ability to reduce ferric to ferrous ions [15]. Moreover, the d-ROMs and BAP tests only need a small amount of blood, and require only 15 min for measurement. Therefore, these methods are prompt and reliable, and suitable for evaluating redox states in patients.

Previous studies using postmortem organs or positron emission tomography imaging have demonstrated regional enhancement of oxidative stress in the brain lesions of stroke-like episodes and the heart lesions of cardiomyopathy in patients carrying A3243G [11–13]. Although enhanced oxidative stress due to A3243G has been proven in these lesions, systemic oxidative stress in patients carrying A3243G has not been evaluated to date. The present study demonstrated a systemic and underlying imbalance of redox states in these patients.

The present study has some limitations. (1) The 'non-stroke type' group included only 4 patients. (2) The mean

age of 'non-stroke type' patients was likely older than that of 'stroke type' patients. (3) The 'stroke type' group included only 2 of 10 patients with cardiomyopathy or diabetes, which might affect the systemic redox states. (4) All of the 10 'stroke type' patients received antioxidant therapy, but only 1 of the 4 'non-stroke type' patients received antioxidant therapy. (5) This study did not show any significant difference in either value of oxidative stress or antioxidant activity between the 'stroke type' and 'non-stroke type' groups. (6) The possibility that the 'non-stroke type' patients in this study will also subsequently develop stroke-like episodes cannot be ruled out. Further studies are necessary to confirm our preliminary results.

Taken together, the d-ROMs and BAP tests clearly demonstrated an abnormality of redox states in patients carrying A3243G. In particular, enhanced oxidative stress in patients with a history of stroke-like episodes may reflect severe mitochondrial dysfunction, which would contribute to the emergence of stroke-like episodes. In addition, in patients without stroke-like episodes, consumption of antioxidant activity may indicate latent oxidative stress. These findings suggested that patients carrying A3243G are always exposed to underlying oxidative stress, and further antioxidant therapy would be beneficial to prevent an intensification of the symptoms.

Acknowledgement

This study was funded in part by the Scientific Research on Innovative Areas (2020021) and Young Scientists (B) (23790985) from the Japan Society for the Promotion of Science.

Disclosure Statement

The authors report no conflicts of interest.

References

- 1 Goto Y, Nonaka I, Horai S: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature* 1990;348:651–653.
- 2 Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome. *Ann Neurol* 1984;16:481–488.
- 3 Vilarinho L, Santorelli FM, Rosas MJ, Tavares C, Melo-Pires M, DiMauro S: The mitochondrial A3243G mutation presenting as severe cardiomyopathy. *J Med Genet* 1997;34:607–609.